var title_f18_53_19280="TB breast";
var content_f18_53_19280=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F68120&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F68120&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Tuberculosis of the breast",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 255px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Tuberculosis of the breast often presents with axillary sinuses.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Michael J Dixon, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_53_19280=[""].join("\n");
var outline_f18_53_19280=null;
var title_f18_53_19281="Patient information: Anemia caused by low iron (The Basics)";
var content_f18_53_19281=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?20/15/20721\">",
"         Patient information: Anemia of chronic disease (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?29/49/30484\">",
"         Patient information: Anemia caused by low iron (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Anemia caused by low iron (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/anemia-caused-by-low-iron-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H41431058\">",
"      <span class=\"h1\">",
"       What is anemia?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Anemia is the term doctors and nurses use when a person has too few red blood cells. Red blood cells are the cells in your blood that carry oxygen. If you have too few red blood cells, your body does not get all the oxygen it needs.",
"     </p>",
"     <p>",
"      Anemia can happen for a few reasons. The most common reason is a lack of iron. This is called &ldquo;iron deficiency anemia.&rdquo; You can have too little iron because:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        You have lost a large amount of blood (this can happen slowly over time, or all of a sudden, because of an injury)",
"       </li>",
"       <li>",
"        Your body cannot absorb enough iron from food",
"       </li>",
"       <li>",
"        You do not get enough iron in your food",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H41431065\">",
"      <span class=\"h1\">",
"       What are the symptoms of iron deficiency anemia?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Many people with iron deficiency anemia have no symptoms. People who do have symptoms might:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Feel tired or weak, especially if they try to exercise or walk up stairs",
"       </li>",
"       <li>",
"        Have headaches",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H41431072\">",
"      <span class=\"h1\">",
"       Is there a test for anemia?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes, your doctor or nurse can test your blood for anemia. It shows up on routine blood tests, such as the &ldquo;complete blood count,&rdquo; often called a &ldquo;CBC.&rdquo;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H41431079\">",
"      <span class=\"h1\">",
"       How is iron deficiency anemia treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The first step in treatment is to find out whether your anemia is caused by blood loss. If so, your doctor or nurse will want to find out why you are bleeding. Then he or she will suggest ways to stop or slow the bleeding.",
"     </p>",
"     <p>",
"      In women, blood loss is often tied to heavy periods. In men and in women who no longer have periods, blood loss can be tied to stomach ulcers or bowel problems.",
"     </p>",
"     <p>",
"      Whatever the cause of your anemia, your doctor or nurse can treat it with iron in pills or shots. If the anemia is severe, you might need a blood transfusion.",
"     </p>",
"     <p>",
"      Most people with iron deficiency anemia need to take extra iron. Eating foods with iron will not do enough to cure the anemia. The iron used in treatment can come in pills or as a shot. Most people get it in pills. Your doctor or nurse will tell you how much to take, and for how long.",
"     </p>",
"     <p>",
"      Iron pills can cause side effects such as upset stomach and constipation (too few bowel movements). If you have side effects, do not stop taking the iron. Instead, ask your doctor or nurse what to do. He or she can suggest ways to reduce these side effects.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H41431086\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?20/15/20721?source=see_link\">",
"       Patient information: Anemia of chronic disease (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?29/49/30484?source=see_link\">",
"       Patient information: Anemia caused by low iron (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?18/53/19281?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15339 Version 3.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-89.32.226.102-A29514B2C0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_53_19281=[""].join("\n");
var outline_f18_53_19281=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H41431058\">",
"      What is anemia?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H41431065\">",
"      What are the symptoms of iron deficiency anemia?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H41431072\">",
"      Is there a test for anemia?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H41431079\">",
"      How is iron deficiency anemia treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H41431086\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?29/49/30484?source=related_link\">",
"      Patient information: Anemia caused by low iron (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?20/15/20721?source=related_link\">",
"      Patient information: Anemia of chronic disease (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_53_19282="Erysipelas of the leg";
var content_f18_53_19282=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F82542&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F82542&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Erysipelas of the leg",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 381px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Erysipelas of the lower leg. The rash is intensely red, sharply demarcated, swollen, and indurated.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Berg D, Worzala K. Atlas of Adult Physical Diagnosis. Philadelphia: Lippincott Williams &amp; Wilkins, 2006. Copyright &copy; 2006 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_53_19282=[""].join("\n");
var outline_f18_53_19282=null;
var title_f18_53_19283="Erythema multiforme target2";
var content_f18_53_19283=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F79955&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F79955&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Target lesions of erythema multiforme",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Target lesions with central bullae are present on the hand.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_53_19283=[""].join("\n");
var outline_f18_53_19283=null;
var title_f18_53_19284="Biliopancreatic diversion";
var content_f18_53_19284=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F67432&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F67432&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 522px\">",
"   <div class=\"ttl\">",
"    Biliopancreatic diversion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 502px; height: 677px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The biliopancreatic diversion procedure consists of a partial gastrectomy and gastroileostomy with a long segment of Roux limb and a short common channel (the part of the small bowel that receives both food and biliopancreatic secretions), resulting in fat and starch malabsorption. The use of this procedure results in high rates of protein malnutrition, anemia, diarrhea, and stomal ulceration, limiting its use.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_53_19284=[""].join("\n");
var outline_f18_53_19284=null;
var title_f18_53_19285="Lymph nodes head and neck";
var content_f18_53_19285=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F69528&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F69528&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 588px\">",
"   <div class=\"ttl\">",
"    Lymph nodes of the head and neck",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 568px; height: 480px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This drawing schematically depicts the major lymph nodes in the head and neck area that are likely to be enlarged on physical examination in patients with various local or systemic diseases. The major nodal groups are shown here in bold, with the areas draining into these nodal groups noted when appropriate. While enlargement of both the left and right supraclavicular lymph nodes may reflect disease in the thorax, left supraclavicular nodal enlargement, because of its drainage pattern, may also reflect the presence of abdominal involvement (ie, Virchow's node).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_53_19285=[""].join("\n");
var outline_f18_53_19285=null;
var title_f18_53_19286="Ischemic stroke treatment";
var content_f18_53_19286=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Ischemic stroke treatment (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?18/53/19286/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/53/19286/contributors\" id=\"au1625\">",
"       Louis R Caplan, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?18/53/19286/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/53/19286/contributors\" id=\"se4371\">",
"       Scott E Kasner, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?18/53/19286/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/53/19286/contributors\" id=\"de6967\">",
"       John F Dashe, MD, PhD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?18/53/19286?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      STROKE OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     In the United States, approximately 700,000 strokes occur each year, most of which are caused by a blockage in blood flow. This blockage causes a lack of blood flow to portions of the brain. The brain injury is called ischemia (literally, lack of blood).",
"    </p>",
"    <p>",
"     During a stroke, one or more areas of the brain can be damaged. Depending upon the area affected, a person may lose the ability to move one side of the body, the ability to speak, the ability to see normally, or a number of other functions. The damage may be temporary or permanent, and the function may be partially or completely lost. A person's long term outcome depends upon how much brain is damaged, how quickly treatment begins, and a number of other factors.",
"    </p>",
"    <p>",
"     Strokes are a leading cause of long-lasting injury, disability, and death. Early treatment and preventive measures can reduce the brain damage that occurs as a result of a stroke. The treatment of a stroke depends upon the type of stroke (eg, ischemic or hemorrhagic), the time since the first stroke symptoms occurred, and the patient's underlying medical problems. General information about the treatment of ischemic strokes is provided here.",
"    </p>",
"    <p>",
"     A separate topic review is available that discusses the signs, symptoms, and diagnosis of ischemic and hemorrhagic strokes. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?37/37/38484?source=see_link\">",
"      \"Patient information: Stroke symptoms and diagnosis (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     A topic is also available that discusses the treatment of hemorrhagic stroke. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?7/63/8180?source=see_link\">",
"      \"Patient information: Hemorrhagic stroke treatment (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      EARLY STROKE TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     For people who have an ischemic stroke, the goal of treatment is to restore blood flow to the affected area of the brain as quickly as possible. The medicines used for the early treatment of ischemic stroke are alteplase, aspirin, and anticoagulants.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3\">",
"     <span class=\"h2\">",
"      Alteplase (thrombolytic therapy)",
"     </span>",
"     &nbsp;&mdash;&nbsp;Thrombolytic therapy uses a medication called tissue plasminogen activator (tPA, alteplase). tPA works to dissolve clots that are blocking blood flow within arteries of the brain. The benefit of thrombolytic treatment slowly decreases over several hours. Thus, the earlier the treatment is given, the more likely the artery can be opened.",
"    </p>",
"    <p>",
"     The use of thrombolytics for acute stroke requires care in a hospital that is able to coordinate emergency services and offers rapid consultation with a neurologist (physician who specializes in the brain) and has intensive care services and imaging (eg, CT scan or MRI). Not all hospitals are able to provide these services, and in this situation it may be necessary to transfer the patient to a hospital that can. It is best if the ambulance or family can bring the stroke patient directly to a hospital that is able to give this care, rather than to transfer the patient later.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h3\">",
"      Side effects",
"     </span>",
"     &nbsp;&mdash;&nbsp;Overall, it is estimated that alteplase treatment is 10 times more likely to help than to harm. However, approximately 1 in 15 patients who is given thrombolytic therapy develops excessive bleeding (hemorrhage) in the brain; this type of bleeding can be fatal. It is estimated that of 30 patients treated, one is harmed by the treatment.",
"    </p>",
"    <p>",
"     When used to treat large numbers of stroke patients, the potential benefits of this treatment outweigh the risks; however, in any individual patient, the decision to take thrombolytic therapy is a very personal one.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      Aspirin",
"     </span>",
"     &nbsp;&mdash;&nbsp;Antiplatelet therapy helps prevent new clots from developing. Unlike thrombolytic drugs, these agents do not dissolve clots that are already present. They are often used acutely if thrombolytic drugs cannot be given or after thrombolytics have been given.",
"    </p>",
"    <p>",
"     Aspirin is the only antiplatelet agent that has been established as effective for the early treatment of acute ischemic stroke. Thus, doctors may use early aspirin therapy (within 48 hours of the start of stroke symptoms) for patients with ischemic stroke who are not receiving alteplase or anticoagulants. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/60/31688?source=see_link&amp;anchor=H2#H2\">",
"      \"Antithrombotic treatment of acute ischemic stroke and transient ischemic attack\", section on 'Antiplatelet agents'",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Platelets are tiny cell fragments circulating in the blood that normally clump together to stop bleeding. This clumping leads to the formation of a blood clot. In strokes, platelets clump together and form clots inside of narrowed arteries. The platelet \"plug\" itself",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     the clot that forms around the plug can block blood flow in the brain.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14511937\">",
"     <span class=\"h2\">",
"      Anticoagulants",
"     </span>",
"     &nbsp;&mdash;&nbsp;Anticoagulants are often, but incorrectly, referred to as blood thinners. They work by decreasing the formation of additional blood clots. Heparin and low molecular weight heparin are anticoagulants.",
"    </p>",
"    <p>",
"     Because of the risk of excessive bleeding, anticoagulation is seldom recommended for the treatment of patients with acute ischemic stroke. However, anticoagulant therapy with heparin or low molecular weight heparin is used by some practitioners for certain types of stroke. For example, some doctors use anticoagulants for the early treatment of stroke caused by blood clots that travel from the heart (cardioembolism) in patients who have heart valve disease or severe heart failure, and for patients who have stroke caused by dissection (a tear of the inner blood vessel wall) of a large artery that supplies blood to the brain. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/60/31688?source=see_link&amp;anchor=H6#H6\">",
"      \"Antithrombotic treatment of acute ischemic stroke and transient ischemic attack\", section on 'Parenteral anticoagulation'",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H14511908\">",
"     <span class=\"h1\">",
"      LONG TERM PREVENTION OF ISCHEMIC STROKE",
"     </span>",
"    </p>",
"    <p>",
"     For people who have already had an ischemic stroke, doctors often prescribe medicines that can prevent another stroke from happening. This is called secondary prevention. The treatments for secondary prevention of ischemic stroke include antiplatelet medications, anticoagulants, and surgical procedures to reopen blockages in blood vessels (revascularization).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14511916\">",
"     <span class=\"h2\">",
"      Antiplatelet therapy",
"     </span>",
"     &nbsp;&mdash;&nbsp;The antiplatelet medicines aspirin, clopidogrel, and the combination of aspirin plus extended-release dipyridamole (Aggrenox) are all acceptable options for preventing recurrent ischemic stroke for patients other than those who have a stroke caused by embolism from the heart. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/35/2618?source=see_link\">",
"      \"Antiplatelet therapy for secondary prevention of stroke\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h3\">",
"      Dipyridamole",
"     </span>",
"     &nbsp;&mdash;&nbsp;Dipyridamole is a medication that may be given after a stroke to reduce the risk of another stroke. It is often given in an extended-release form, which combines dipyridamole with aspirin (called Aggrenox&reg;, which contains extended-release dipyridamole 200 mg and 25 mg aspirin). It is taken two times per day. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/35/2618?source=see_link&amp;anchor=H8#H8\">",
"      \"Antiplatelet therapy for secondary prevention of stroke\", section on 'Dipyridamole'",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Side effects of dipyridamole include headache, stomach upset,",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     diarrhea. Headaches usually improve over the first week.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h3\">",
"      Clopidogrel",
"     </span>",
"     &nbsp;&mdash;&nbsp;Clopidogrel (Plavix&reg;) is an antiplatelet medication that is also used in patients after stroke to reduce the risk of having another stroke. In one trial, the combined risk of stroke, MI, or vascular death, was modestly reduced with clopidogrel treatment compared with aspirin treatment, and the result was statistically significant. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/35/2618?source=see_link&amp;anchor=H5#H5\">",
"      \"Antiplatelet therapy for secondary prevention of stroke\", section on 'Clopidogrel'",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     For this reason, some experts recommend use of clopidogrel for patients who are not treated with the combination of aspirin and extended release dipyridamole, rather than use of aspirin alone. Compared with aspirin, clopidogrel causes a slightly higher frequency of rash and diarrhea, and a slightly lower frequency of stomach upset and gastrointestinal bleeding.",
"    </p>",
"    <p>",
"     Clopidogrel is not usually recommended in combination with aspirin after a stroke because the combination is no more effective for preventing another stroke than either clopidogrel or aspirin alone, while using the two in combination increases the risk of bleeding in the brain. However, selected patients with a recent acute myocardial infarction, other acute coronary syndrome, or recent arterial stent placement are often treated with the combination of clopidogrel plus aspirin.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h3\">",
"      Aspirin",
"     </span>",
"     &nbsp;&mdash;&nbsp;Aspirin is effective for preventing ischemic stroke. Most studies have found that 50 to 325",
"     <span class=\"nowrap\">",
"      mg/day",
"     </span>",
"     of aspirin is as effective as higher doses for preventing stroke. Furthermore, lower doses within this range appear to provide the same benefit as higher doses. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/35/2618?source=see_link&amp;anchor=H2#H2\">",
"      \"Antiplatelet therapy for secondary prevention of stroke\", section on 'Aspirin'",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     In the United States, one advantage of aspirin compared to other antiplatelet medications is cost; one month of aspirin costs approximately $3 compared to at least $160 per month for combined dipyridamole and aspirin and at least $135 per month for clopidogrel.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h2\">",
"      Anticoagulant therapy",
"     </span>",
"     &nbsp;&mdash;&nbsp;Anticoagulant therapy is used to prevent stroke for selected patients. As an example, for long-term stroke prevention, virtually all patients with atrial fibrillation who have a history of embolic stroke or transient ischemic attack should be treated with anticoagulation (warfarin or dabigatran) in the absence of contraindications.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h3\">",
"      Warfarin",
"     </span>",
"     &nbsp;&mdash;&nbsp;Warfarin (Coumadin&reg;) is a pill that is taken by mouth. It is often recommended as a long-term treatment for people who have conditions that promote the formation of blood clots, such as atrial fibrillation of the heart. People who take warfarin must be closely monitored with blood tests to ensure that the correct dose is used and that the risk of excessive bleeding or developing blood clots is minimized. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/15/21747?source=see_link\">",
"      \"Patient information: Warfarin (Coumadin) (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13827322\">",
"     <span class=\"h3\">",
"      Dabigatran",
"     </span>",
"     &nbsp;&mdash;&nbsp;Dabigatran (Pradaxa&reg;) is another medication that is used to thin the blood. It is useful for people who have atrial fibrillation of the heart. Dabigatran is taken twice a day. Unlike warfarin, patients who take dabigatran do not need to be monitored with blood tests. However, dabigatran is more expensive than warfarin. (See",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?0/58/933?source=see_link\">",
"      \"Dabigatran: Patient drug information\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h2\">",
"      Revascularization",
"     </span>",
"     &nbsp;&mdash;&nbsp;Revascularization is the medical term for reestablishing blood flow to an area. In people who have had a stroke, revascularization usually refers to a surgical procedure (carotid endarterectomy) that opens a blocked artery in the neck (the carotid artery), which improves blood flow to the brain and reduces the risk of stroke. The amount of blockage in the carotid artery can be measured with an ultrasound imaging test, CT angiogram, MRA, or conventional arteriogram. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?37/37/38484?source=see_link\">",
"      \"Patient information: Stroke symptoms and diagnosis (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Carotid endarterectomy is most successful when it is performed by a vascular surgeon who has specialized training and experience with the procedure. However, even in experienced hands, the procedure has risks, including bleeding, brain injury, stroke, and even death. Some people are likely to benefit from carotid endarterectomy while for others, the risks of the procedure are greater than the potential benefits. Placement of a stent in the carotid artery is another alternative, although this therapy carries a greater risk of stroke and disability, especially in people over the age of 70 years. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/1/21530?source=see_link\">",
"      \"Management of symptomatic carotid atherosclerotic disease\"",
"     </a>",
"     and",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/33/16922?source=see_link\">",
"      \"Management of asymptomatic carotid atherosclerotic disease\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H13\">",
"     <span class=\"h1\">",
"      COMPLICATIONS AFTER STROKE",
"     </span>",
"    </p>",
"    <p>",
"     A number of problems can develop in people who have had a stroke. These complications are significant because approximately half of deaths after stroke are due to medical complications. In the days and weeks after a stroke, clinicians, the patient, and family members can work to decrease the risk of some of these complications. Common complications include the following:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Blood clots",
"      </li>",
"      <li>",
"       Difficulty eating and drinking, which increases the risk of pneumonia and malnutrition",
"      </li>",
"      <li>",
"       Pneumonia",
"      </li>",
"      <li>",
"       Urinary tract infection",
"      </li>",
"      <li>",
"       Bleeding in the digestive system",
"      </li>",
"      <li>",
"       Falls",
"      </li>",
"      <li>",
"       Heart attack or heart failure",
"      </li>",
"      <li>",
"       Bed sores",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/12/17610?source=see_link\">",
"      \"Medical complications of stroke\"",
"     </a>",
"     and",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/54/10087?source=see_link\">",
"      \"Stroke-related pulmonary complications and abnormal respiratory patterns\"",
"     </a>",
"     and",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/20/26952?source=see_link\">",
"      \"Cardiac complications of stroke\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h2\">",
"      Blood clots",
"     </span>",
"     &nbsp;&mdash;&nbsp;People who have strokes are at an increased risk of developing blood clots as they recover. A deep vein thrombosis (DVT) is a blood clot that develops in the deep veins of the leg. If the clot breaks off, it can travel to the lung, where it is called a pulmonary embolus (PE). A PE can cause serious, and potentially fatal, changes in blood flow throughout the body. These blood clots occur most often between the second and seventh day after the stroke.",
"    </p>",
"    <p>",
"     The risk of pulmonary embolism is especially high in stroke patients who have difficulty with moving or walking around during the recovery period. Difficulty walking may be related to paralysis caused by the stroke or to other medical conditions. Lack of movement increases the risk of a deep vein thrombosis",
"    </p>",
"    <p>",
"     Heparin or low molecular weight heparin is used commonly to prevent blood clots in patients who are recovering from a stroke, especially if the patient has difficulty moving or walking without assistance. In this situation, anticoagulation can help to prevent a blood clot in a deep vein of the leg or a blood clot that travels to the lung (called a pulmonary embolism). (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?12/44/12998?source=see_link\">",
"      \"Patient information: Deep vein thrombosis (DVT) (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Use of an anticoagulant to prevent blood clots is different that anticoagulation used for treatment of an ischemic stroke; the dose used for prevention is typically smaller than that used to treat stroke.",
"    </p>",
"    <p>",
"     To decrease the risk of blood clots, the patient is encouraged to get up and move around frequently as soon as they are able to do so. A physical therapist is often available to help, especially if the patient has weakness in the legs as a result of the stroke.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h2\">",
"      Difficulty swallowing",
"     </span>",
"     &nbsp;&mdash;&nbsp;The act of swallowing requires coordination of the nerves and muscles of the tongue, mouth, and throat. The brain damage that occurs as a result of a stroke can cause muscle weakness and difficulty swallowing. Dysphagia is the medical term for difficulty swallowing.",
"    </p>",
"    <p>",
"     Dysphagia is concerning because it increases the risk of inhaling saliva or food into the lungs, which can cause a type of pneumonia known as aspiration pneumonia. Patients with stroke-related pneumonia have a higher risk of death and a poorer long-term outcome when compared to patients without pneumonia. However, in people who have weakness of one side of the body, dysphagia is often temporary because both sides of the brain and body control swallowing.",
"    </p>",
"    <p>",
"     To determine if a patient is at risk for inhaling food or drinks into the lungs, a simple water swallow test may be done. If the patient has difficulty swallowing water, the clinician may recommend that the patient not eat or drink anything temporarily. In the meantime, medication and nutrition can be given into a vein. Specific exercises and training programs can help to retrain a person how to swallow despite muscle or nerve damage. An additive to thicken liquids may be recommended.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H16\">",
"     <span class=\"h2\">",
"      Urinary tract infection",
"     </span>",
"     &nbsp;&mdash;&nbsp;Urinary tract infections are a common complication after stroke, occurring in about 11 percent of patients during the first three months after stroke. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/12/17610?source=see_link&amp;anchor=H15#H15\">",
"      \"Medical complications of stroke\", section on 'Urinary tract infection'",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     After a stroke, some men and women have difficulty getting out of bed to empty their bladder. Others have difficulty with urinary leakage or are not able to empty their bladder completely because of muscle weakness. For these reasons, a catheter is often placed inside the bladder, especially during the first few days to weeks after a stroke. However, there is an increased risk of urinary tract infections related to the use of a catheter.",
"    </p>",
"    <p>",
"     There are a number of strategies that can decrease the risk of urinary tract infections in patients who require a catheter. A few of these strategies are listed below:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Use a catheter only when necessary",
"      </li>",
"      <li>",
"       Remove the catheter as soon as possible",
"      </li>",
"      <li>",
"       It is not necessary to change the catheter to prevent infections. The catheter should only be changed if it begins to crack or deteriorate or if the patient has a urinary tract infection.",
"      </li>",
"      <li>",
"       For men, there is a lower risk of infections with a condom-type catheter.",
"      </li>",
"      <li>",
"       There are not good data to support using antibiotics to prevent infection during catheter use. Antibiotics are recommended to treat a urinary tract infection if it develops.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H17\">",
"     <span class=\"h2\">",
"      Nutrition",
"     </span>",
"     &nbsp;&mdash;&nbsp;After a stroke, some patients have difficulty consuming an adequate number of calories. In addition, some patients are underweight or malnourished before their stroke. These problems can interfere with a person's ability to recover from stroke, potentially increasing the risk of long-term disability.",
"    </p>",
"    <p>",
"     For these reasons, a patient's nutritional status should be evaluated before discharge from the hospital. This includes a review of the patient's past and current body weight, a basic history of the patient's eating habits, blood testing, and a physical examination that focuses on the condition of the eyes, hair, skin, mouth, and muscles.",
"    </p>",
"    <p>",
"     If a person is not able to consume an adequate number of calories, a feeding tube may be placed through the nose and into the stomach (called a nasogastric tube). If the feeding tube will be needed for more than two to three weeks, a tube can be inserted through the abdomen into the stomach (called a percutaneous endoscopic gastrostomy (PEG) tube). The PEG tube may be removed if the person regains the ability to eat normally.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18\">",
"     <span class=\"h2\">",
"      GI bleeding",
"     </span>",
"     &nbsp;&mdash;&nbsp;Patients who have had a severe stroke, especially those who are in the intensive care unit and require a ventilator to breathe, have an increased risk of developing a bleeding ulcer in the stomach. To lower this risk, a medication can be given to lower the stomach's production of acid.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H19\">",
"     <span class=\"h2\">",
"      Heart problems",
"     </span>",
"     &nbsp;&mdash;&nbsp;Heart problems, such as an irregular heart rhythm (called an arrhythmia) or heart attack (called a myocardial infarction) are commonly seen following stroke, with some heart problems occurring in up to 70 percent of people. It is important to determine whether the heart problems are caused by the stroke, unrelated to it, or the cause of the stroke.",
"    </p>",
"    <p>",
"     Tests often performed to screen for these problems include an electrocardiogram (ECG), blood testing, and continuous monitoring of the heart rhythm (called telemetry). Because a large number of people with ischemic strokes also have coronary artery disease, there is a risk of ischemia (lack of blood flow) in the heart during the stroke. In some cases, the person may not be able to tell the clinician that he or she feels chest pain. The ECG will help the clinician to diagnose and treat heart problems as quickly as possible.",
"    </p>",
"    <p>",
"     Other heart testing may also be recommended, such as an echocardiogram. This test uses sound waves to examine the heart and the aorta (the large vessel that arises directly from the heart); blood vessels that supply the brain with blood originate from the aorta (",
"     <a class=\"graphic graphic_figure graphicRef74006 \" href=\"UTD.htm?40/23/41329\">",
"      figure 1",
"     </a>",
"     ). In some people with embolic strokes, the heart or the aorta is the source of the blood clot that led to the stroke.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H20\">",
"     <span class=\"h2\">",
"      Bed sores",
"     </span>",
"     &nbsp;&mdash;&nbsp;Bed sores are areas of skin and underlying tissue that are injured when compressed between a bone (eg, tail bone) and an external surface (eg, a mattress) for a prolonged period of time. Other names for bed sores are pressure sores and decubitus ulcers.",
"    </p>",
"    <p>",
"     The consequences of this type of skin injury range from mild skin redness to deep ulcers extending down to the bone. The ulcer can be uncomfortable and increases the risk of infection for the patient and also potentially increases the healthcare costs and hospital stay.",
"    </p>",
"    <p>",
"     Bed sores are common in people with a limited ability to move without assistance, and may be preventable by moving or turning (or being moved by a family member or nurse) at least every two hours. It is recommended that:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Patients should be placed at a 30 degree angle when lying on their side to avoid direct pressure over the hip bone (greater trochanter).",
"      </li>",
"      <li>",
"       Pillows or foam wedges may need to be placed between the ankles and knees to avoid pressure at these sites.",
"      </li>",
"      <li>",
"       The heels require particular attention; pillows may be placed under the lower legs to elevate the heels, or special heel protectors can be used.",
"      </li>",
"      <li>",
"       Elevation of the head of the bed should be limited.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Chair-bound patients may generate considerable pressures over the sit bones (ischial tuberosities); they should probably be repositioned at least every hour.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H21\">",
"     <span class=\"h2\">",
"      Falls",
"     </span>",
"     &nbsp;&mdash;&nbsp;After a stroke, many people have difficulty walking due to muscle weakness, paralysis, or lack of coordination. When a person becomes less active or unable to walk, they are at increased risk of bone thinning (osteoporosis) and worsened muscle weakness. These risks greatly increase the chance of breaking a bone after a fall. Falls are one of the most common complications of stroke, occurring in up to 25 percent of patients.",
"    </p>",
"    <p>",
"     To reduce the risk of falls, several interventions may be helpful:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Muscle strengthening and balance retraining exercises &mdash; This may include exercise or rehabilitation programs tailored to an individual's needs and abilities. Group classes, such as Tai Chi, may be helpful for patients who are able to walk without assistance.",
"      </li>",
"      <li>",
"       Evaluation of fall risk &mdash; An evaluation may be recommended to determine if a person is at risk for falling. If there is a risk of falling, treatments (eg, a walker, balance training) may be recommended to decrease the risk.",
"      </li>",
"      <li>",
"       Home hazards &mdash; Home hazards such as poor lighting or loose rugs can increase the risk of falling. The following tips can reduce this risk:",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     <ul class=\"hyphen-block\">",
"      <li>",
"       Remove loose rugs, electrical cords, or other items that could lead to tripping, slipping, and falling",
"      </li>",
"      <li>",
"       Ensure that there is adequate lighting in all areas inside and around the home (including stairwells and entrance ways)",
"      </li>",
"      <li>",
"       Avoid walking on ice, wet or polished floors, or other potentially slippery surfaces, and avoid walking in unfamiliar areas outside",
"      </li>",
"      <li>",
"       Ensure that the person has properly fitted, non-slip footwear",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H22\">",
"     <span class=\"h1\">",
"      OUTCOME AFTER STROKE",
"     </span>",
"    </p>",
"    <p>",
"     A patient's healthcare team can often provide guidance to family members regarding the patient's risk of long-term disability or death. However, it may difficult to know exactly what to expect, and in most cases, it is necessary to watch and wait.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H23\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H1804604343\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H2877895\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?23/55/24435?source=see_link\">",
"      Patient information: Stroke (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/37/36435?source=see_link\">",
"      Patient information: Medicines after an ischemic stroke (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?38/40/39554?source=see_link\">",
"      Patient information: Lowering the risk of having another stroke (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?34/22/35170?source=see_link\">",
"      Patient information: Transient ischemic attack (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?29/61/30674?source=see_link\">",
"      Patient information: Aphasia (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?3/45/3795?source=see_link\">",
"      Patient information: Recovery after stroke (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?23/5/23635?source=see_link\">",
"      Patient information: Atherosclerosis (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H2877887\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?37/37/38484?source=see_link\">",
"      Patient information: Stroke symptoms and diagnosis (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?7/63/8180?source=see_link\">",
"      Patient information: Hemorrhagic stroke treatment (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/15/21747?source=see_link\">",
"      Patient information: Warfarin (Coumadin) (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?12/44/12998?source=see_link\">",
"      Patient information: Deep vein thrombosis (DVT) (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H24\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/35/2618?source=see_link\">",
"      Antiplatelet therapy for secondary prevention of stroke",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42506?source=see_link\">",
"      Antithrombotic therapy to prevent embolization in atrial fibrillation",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/20/26952?source=see_link\">",
"      Cardiac complications of stroke",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/16/11530?source=see_link\">",
"      Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/56/24458?source=see_link\">",
"      Cerebrovascular disorders complicating pregnancy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/17/40216?source=see_link\">",
"      Clinical diagnosis of stroke subtypes",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/10/40105?source=see_link\">",
"      Cryptogenic stroke",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/35/569?source=see_link\">",
"      Decompressive hemicraniectomy for malignant middle cerebral artery territory infarction",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/21/18773?source=see_link\">",
"      Definition of transient ischemic attack",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/37/36439?source=see_link\">",
"      Differential diagnosis of transient ischemic attack and stroke",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/63/9208?source=see_link\">",
"      Etiology and classification of stroke",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/26/7594?source=see_link\">",
"      Etiology, clinical features, and diagnosis of cerebral venous thrombosis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/39/38522?source=see_link\">",
"      Etiology, clinical manifestations, and diagnosis of aneurysmal subarachnoid hemorrhage",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/8/41098?source=see_link\">",
"      Reperfusion therapy for acute ischemic stroke",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/11/32953?source=see_link\">",
"      Headache, migraine, and stroke",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/29/33242?source=see_link\">",
"      Initial assessment and management of acute stroke",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/11/10426?source=see_link\">",
"      Initial evaluation and management of transient ischemic attack and minor stroke",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/61/2010?source=see_link\">",
"      Intracranial large artery atherosclerosis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/59/4026?source=see_link\">",
"      Lacunar infarcts",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/12/17610?source=see_link\">",
"      Medical complications of stroke",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/56/17290?source=see_link\">",
"      Neuroimaging of acute ischemic stroke",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/47/28410?source=see_link\">",
"      Overview of the evaluation of stroke",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/22/39273?source=see_link\">",
"      Posterior circulation cerebrovascular syndromes",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/33/32281?source=see_link\">",
"      Secondary prevention for specific causes of ischemic stroke and transient ischemic attack",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/61/30682?source=see_link\">",
"      Secondary prevention of stroke: Risk factor reduction",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/28/29130?source=see_link\">",
"      Spontaneous intracerebral hemorrhage: Pathogenesis, clinical features, and diagnosis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/56/32650?source=see_link\">",
"      Spontaneous intracerebral hemorrhage: Prognosis and treatment",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/54/37738?source=see_link\">",
"      Treatment of aneurysmal subarachnoid hemorrhage",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"      www.nlm.nih.gov/medlineplus/healthtopics.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Institute of Neurological Disorders and Stroke",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     <a class=\"external\" href=\"file://www.ninds.nih.gov/disorders/stroke/stroke.htm\">",
"      www.ninds.nih.gov/disorders/stroke/stroke.htm",
"     </a>",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Stroke Association",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.strokeassociation.org/\">",
"      www.strokeassociation.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Stroke Association",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.stroke.org/\">",
"      www.stroke.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Several books are also recommended:",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     <ul class=\"hyphen-block\">",
"      <li>",
"       Caplan LR. Stroke, American Academy of Neurology and Demos Publishers, New York 2006.",
"      </li>",
"      <li>",
"       Hutton C, Caplan LR. Striking back at stroke: a doctor-patient journal, Dana Press, New York 2003.",
"      </li>",
"      <li>",
"       Hutton C. After a stroke: 300 tips for making life easier, Demos, New York 2005.",
"      </li>",
"     </ul>",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 1, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?18/53/19286?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f18_53_19286=[""].join("\n");
var outline_f18_53_19286=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           STROKE OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           EARLY STROKE TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H14511908\">",
"           LONG TERM PREVENTION OF ISCHEMIC STROKE",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H13\">",
"           COMPLICATIONS AFTER STROKE",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H22\">",
"           OUTCOME AFTER STROKE",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H23\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          FIGURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?40/23/41329\" title=\"figure 1\">",
"           Aorta anatomy PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f18_53_19287="Chemotherapy of ovarian cancer in pregnancy";
var content_f18_53_19287=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Chemotherapy of ovarian cancer in pregnancy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/53/19287/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/53/19287/contributors\">",
"     Carolyn D Runowicz, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/53/19287/contributors\">",
"     Molly Brewer, DVM, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/53/19287/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/53/19287/contributors\">",
"     Barbara Goff, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/53/19287/contributors\">",
"     Deputy Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/53/19287/contributors\">",
"     Don S Dizon, MD, FACP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/53/19287/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?18/53/19287/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 24, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A gynecologic malignancy is estimated to complicate four to eight of every 100,000 pregnancies [",
"    <a class=\"abstract\" href=\"UTD.htm?18/53/19287/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. Unfortunately, the data on the effects of antineoplastic drugs administered during pregnancy have largely been derived from case reports, small case series, and collected reviews of pregnant women treated for a variety of cancers. There are even less data on long-term outcomes in offspring.",
"   </p>",
"   <p>",
"    This topic will address the administration of chemotherapy for women diagnosed with ovarian cancer in pregnancy. In order to optimize treatment outcomes, a pregnant woman with a diagnosis of ovarian cancer should be managed by a multidisciplinary team that includes experts in the fields of maternal-fetal medicine, gynecologic oncology, pediatrics, and pathology.",
"   </p>",
"   <p>",
"    The clinical manifestations and diagnosis of ovarian cancer in pregnancy and surgical management of this disease are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/62/9192?source=see_link\">",
"     \"Clinical manifestations and diagnosis of ovarian cancer in pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/41/4759?source=see_link\">",
"     \"Management of ovarian cancer in pregnant women\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENERAL PRINCIPLES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Concerns about the administration of cytotoxic chemotherapy during pregnancy arise because chemotherapy preferentially kills rapidly proliferating cells, and the fetus represents a rapidly proliferating cell mass. All chemotherapy agents used in the treatment of epithelial and nonepithelial ovarian cancers are pregnancy",
"    <strong>",
"     category D",
"    </strong>",
"    , meaning that fetal exposure to individual chemotherapeutic agents have resulted in adverse effects including intrauterine growth restriction, prematurity, and low birth weight in the infants [",
"    <a class=\"abstract\" href=\"UTD.htm?18/53/19287/abstract/5\">",
"     5",
"    </a>",
"    ]. Chemotherapy may also cause fetal toxicities similar to those observed in the mother (eg, bone marrow suppression).",
"   </p>",
"   <p>",
"    The risks of spontaneous abortion, fetal death, and major malformations vary depending on the agent used and the trimester of pregnancy. These risks must be weighed against the benefits of immediate versus delayed (ie, postdelivery) chemotherapy for the mother. Ethical considerations of treatment during pregnancy have emphasized the role of patient autonomy and the concept of beneficence and nonmaleficence for both the mother and fetus [",
"    <a class=\"abstract\" href=\"UTD.htm?18/53/19287/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The impact of treatment on pregnancy outcomes depends on two factors: the regimen used and when it is administered. These are discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27955600\">",
"    <span class=\"h2\">",
"     Multiagent versus single agent chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of fetal malformations is higher with multiagent than single agent chemotherapy (approximately 25 versus 10 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/53/19287/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. By comparison, two to three percent of infants in the general population are diagnosed with a congenital malformation around the time of birth.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27955677\">",
"    <span class=\"h2\">",
"     Treatment during first trimester versus later",
"    </span>",
"    &nbsp;&mdash;&nbsp;The impact of chemotherapy during pregnancy depends on when treatment is administered:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      During the first four weeks of gestation (first two weeks post conception) the embryo is undifferentiated. Fetal exposure to cytotoxic agents at this point results in \"all or none\" phenomena: either the pregnancy is lost or it continues with no apparent adverse effect [",
"      <a class=\"abstract\" href=\"UTD.htm?18/53/19287/abstract/5,9\">",
"       5,9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Organogenesis occurs during weeks five to ten weeks of gestation. The administration of cytotoxic drugs, particularly antimetabolites (eg, 5-fluorouracil and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      ) and alkylating agents (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/10/10408?source=see_link\">",
"       busulfan",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/52/35654?source=see_link\">",
"       chlorambucil",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      ), during this period carries an increased risk of fetal malformations. A review of 217 pregnant women treated with chemotherapy (for a variety of malignancies) between 1983 and 1995 reported the following outcomes: congenital abnormalities in 18 newborns, chromosomal abnormalities in two, stillbirth in four, and spontaneous abortion in 15 cases [",
"      <a class=\"abstract\" href=\"UTD.htm?18/53/19287/abstract/10\">",
"       10",
"      </a>",
"      ]. The majority of stillborn infants and infants with chromosomal or congenital abnormalities had mothers who were given chemotherapy in the first trimester.",
"     </li>",
"     <li>",
"      When chemotherapy is delivered to the mother during the second and third trimesters of pregnancy, the risk of fetal malformation is low. In one review, the incidence of fetal malformations in 150 women given chemotherapy during the second or third trimesters of pregnancy was 1.3 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?18/53/19287/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Administration of chemotherapy within three weeks of anticipated delivery or beyond 35 weeks of gestation may induce neonatal myelosuppression and complicate delivery due to adverse effects of treatment on bone marrow reserves. This includes potential complications such as bleeding, sepsis, and death. Additionally, neonatal toxicity may be higher if chemotherapy is administered peripartum because placental drug clearance is generally more effective than either hepatic",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      renal drug clearance in the neonate [",
"      <a class=\"abstract\" href=\"UTD.htm?18/53/19287/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     OVARIAN CANCER DURING PREGNANCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several different histologic types of malignancy that can arise within the ovary including epithelial ovarian cancer (EOC), ovarian germ cell tumors, and sex-cord stromal tumors. In some series of women presenting with an ovarian malignancy while pregnant, germ cell tumors predominate, while others report a higher frequency of EOC. The indications and medical treatment of ovarian cancer during pregnancy by histologic type is discussed below. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/62/9192?source=see_link&amp;anchor=H13#H13\">",
"     \"Clinical manifestations and diagnosis of ovarian cancer in pregnancy\", section on 'Malignant ovarian tumors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H84410292\">",
"    <span class=\"h1\">",
"     EPITHELIAL OVARIAN CANCER",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following surgery, the indications for adjuvant treatment of epithelial ovarian cancer (EOC) are similar for pregnant and nonpregnant women. However, administration of chemotherapy during the first trimester",
"    <strong>",
"     should be avoided",
"    </strong>",
"    . We recommend chemotherapy for:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Women with early stage EOC (",
"      <a class=\"graphic graphic_table graphicRef51205 \" href=\"UTD.htm?14/43/15038\">",
"       table 1",
"      </a>",
"      ) if any of the following high-risk features is present: stage",
"      <span class=\"nowrap\">",
"       IA/IB,",
"      </span>",
"      grade",
"      <span class=\"nowrap\">",
"       2/3;",
"      </span>",
"      stage IC or II (any histology); serous or clear cell carcinoma (stage IA, IB, IC, or II)",
"     </li>",
"     <li>",
"      Women with stage III or IV EOC",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H294838285\">",
"    <span class=\"h2\">",
"     Regimen",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with nonpregnant women, we recommend the use of a platinum drug (with or without a taxane) for women with EOC in pregnancy because, in general, this combination results in the best survival outcomes. For women diagnosed during pregnancy, we prefer",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    because it is a better tolerated agent. There are little data to guide the use of taxanes in pregnancy, although it has also been used to treat breast cancer in pregnancy without apparent adverse events [",
"    <a class=\"abstract\" href=\"UTD.htm?18/53/19287/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. However, if a taxane is administered, we prefer",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    rather than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    because it is less myelotoxic in general.",
"   </p>",
"   <p>",
"    All women with EOC in pregnancy should be informed of the limited data on maternal and fetal outcomes associated with treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H294838014\">",
"    <span class=\"h3\">",
"     Platinum",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although there are low quality data to support the administration of platinum in the second or third trimester of pregnancy, it appears to be feasible [",
"    <a class=\"abstract\" href=\"UTD.htm?18/53/19287/abstract/5,14-27\">",
"     5,14-27",
"    </a>",
"    ]. There are low quality data to indicate whether",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    should be preferentially administered in women with EOC during pregnancy. As in the case of nonpregnant women, however, we suggest carboplatin because it is better tolerated and reduces the risk of long-term side effects (eg, renal and neurotoxicity). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/11/21689?source=see_link&amp;anchor=H250842535#H250842535\">",
"     \"First-line chemotherapy for advanced (stage III or IV) epithelial ovarian, fallopian tubal, and peritoneal cancer\", section on 'Platinum and taxane combination therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a systematic review on the use of platinum derivatives in 43 pregnant women (36 with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    , six with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    , and one case where both drugs were administered), the major findings were [",
"    <a class=\"abstract\" href=\"UTD.htm?18/53/19287/abstract/25\">",
"     25",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Exposure to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      was associated with eight adverse effects to the fetus including intrauterine growth restriction (three), preterm birth (three), oligohydramnios (two), polyhydramnios (one), and ventriculomegaly (one). One case of microphthalmos occurred but cisplatin was administered in the first trimester in this case as part of a regimen that is no longer used (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/49/4887?source=see_link\">",
"       dacarbazine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/39/33399?source=see_link\">",
"       carmustine",
"      </a>",
"      , and cisplatin).",
"     </li>",
"     <li>",
"      No malformations or toxicity were reported among seven",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"       carboplatin",
"      </a>",
"      -exposed neonates.",
"     </li>",
"     <li>",
"      Detectable",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      levels or platinum DNA adducts were observed in neonates when chemotherapy was delivered in the third trimester or close to delivery suggesting transplacental transfer.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H294838021\">",
"    <span class=\"h3\">",
"     Taxanes",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is minimal information on pregnancy outcome in women who received taxanes for ovarian cancer in pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?18/53/19287/abstract/12,28\">",
"     12,28",
"    </a>",
"    ]. No first trimester exposures have been reported. Literature reviews describe women treated with taxanes (mostly",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    ) in the second or third trimester and there were no adverse fetal or neonatal effects. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/11/21689?source=see_link&amp;anchor=H250842535#H250842535\">",
"     \"First-line chemotherapy for advanced (stage III or IV) epithelial ovarian, fallopian tubal, and peritoneal cancer\", section on 'Platinum and taxane combination therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H294839653\">",
"    <span class=\"h2\">",
"     Administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients can be treated with single agent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    or a combination of carboplatin and a taxane. A decision should be made on an individual basis taking into account potential risks and benefits of treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H294839610\">",
"    <span class=\"h3\">",
"     Intraperitoneal (IP) therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;IP chemotherapy is an option for women with optimally cytoreduced EOC, but it has not been evaluated in pregnant patients. We do not recommend administration of IP chemotherapy in these patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/11/21689?source=see_link&amp;anchor=H250842013#H250842013\">",
"     \"First-line chemotherapy for advanced (stage III or IV) epithelial ovarian, fallopian tubal, and peritoneal cancer\", section on 'Intraperitoneal chemotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H294838311\">",
"    <span class=\"h2\">",
"     Timing of chemotherapy",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H294838341\">",
"    <span class=\"h3\">",
"     Early stage disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;For pregnant women with high risk early stage EOC, we suggest initiation of chemotherapy following completion of the first trimester. The approach is similar to the treatment of nonpregnant women with early stage EOC. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Indications'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/39/26231?source=see_link&amp;anchor=H2#H2\">",
"     \"Adjuvant therapy of early stage (stage I and II) epithelial ovarian, fallopian tubal, or peritoneal cancer\", section on 'Choice of adjuvant treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For women who prefer not to receive treatment during pregnancy due to concerns for fetal safety, it may be reasonable to delay adjuvant chemotherapy until after delivery. The evidence to support this comes from two studies that evaluated the impact of a treatment start delay [",
"    <a class=\"abstract\" href=\"UTD.htm?18/53/19287/abstract/29\">",
"     29",
"    </a>",
"    ]. In these trials, 271 nonpregnant women with high-risk stage I EOC were randomly assigned treatment with adjuvant",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    versus observation (trial 1) or P-32 (trial 2). In both trials, women who were not treated with cisplatin received cisplatin at the time of relapse. The main results were:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Administration of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      reduced the risk of relapse in both trials (compared to observation, HR 0.35, 95% CI 0.14-0.89; compared to P-32, HR 0.39, 95% CI 0.19-0.77).",
"     </li>",
"     <li>",
"      There was no difference in five year overall survival (88 and 82 percent with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      or observation; HR 1.15, 95% CI 0.44-2.98; 81 and 79 percent with cisplatin or P-32, HR 0.72m 95% CI 0.72, 95% CI 0.37-1.43).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H294838374\">",
"    <span class=\"h3\">",
"     Advanced stage disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with advanced disease should begin chemotherapy as soon as they are out of the first trimester and have recovered from surgery. We generally prefer to initiate treatment in two to four weeks after surgery for ovarian cancer. The approach to treatment is similar to that for nonpregnant women with advanced EOC. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/11/21689?source=see_link&amp;anchor=H20367464#H20367464\">",
"     \"First-line chemotherapy for advanced (stage III or IV) epithelial ovarian, fallopian tubal, and peritoneal cancer\", section on 'Initial chemotherapy'",
"    </a>",
"    .) In non-pregnant patients, dose dense (weekly",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    ) has shown an improvement in progression-free survival and overall survival [",
"    <a class=\"abstract\" href=\"UTD.htm?18/53/19287/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     GERM CELL TUMORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most germ cell ovarian malignancies occur in young women and are limited to one ovary [",
"    <a class=\"abstract\" href=\"UTD.htm?18/53/19287/abstract/3\">",
"     3",
"    </a>",
"    ]. Maximal surgical cytoreduction is usually undertaken initially. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/24/33162?source=see_link\">",
"     \"Treatment of malignant germ cell tumors of the ovary\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/33/38425?source=see_link\">",
"     \"Surgical management of advanced testicular germ cell tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Despite being diagnosed at a relatively early stage, we recommend adjuvant chemotherapy for most women with completely resected malignant ovarian germ cell tumors EXCEPT those with stage IA dysgerminoma (",
"    <a class=\"graphic graphic_table graphicRef51205 \" href=\"UTD.htm?14/43/15038\">",
"     table 1",
"    </a>",
"    ) or stage I grade one immature teratoma. When indicated, chemotherapy should be delayed at least until completion of the first trimester of pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?18/53/19287/abstract/31-33\">",
"     31-33",
"    </a>",
"    ]. The most commonly used regimen is",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    (BEP, (",
"    <a class=\"graphic graphic_table graphicRef65516 \" href=\"UTD.htm?14/2/14382\">",
"     table 2",
"    </a>",
"    )). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/37/5721?source=see_link\">",
"     \"Ovarian germ cell neoplasms: Pathology, clinical manifestations, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/24/33162?source=see_link\">",
"     \"Treatment of malignant germ cell tumors of the ovary\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In other series, use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    during pregnancy has been associated with growth restriction and neonatal bone marrow suppression [",
"    <a class=\"abstract\" href=\"UTD.htm?18/53/19287/abstract/5,9\">",
"     5,9",
"    </a>",
"    ]. Etoposide is teratogenic in mice and rats at doses much lower than the human dose and should not be used in the first trimester.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Timing of chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given that germ cell neoplasms are exquisitely sensitive to platinum-based chemotherapy, several investigators have published case reports addressing a treatment delay until after the completion of the pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?18/53/19287/abstract/34-36\">",
"     34-36",
"    </a>",
"    ]. A summary of findings is presented below:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One case report documents a woman with a yolk sac (endodermal sinus) tumor that was surgically resected at 19 weeks of gestation [",
"      <a class=\"abstract\" href=\"UTD.htm?18/53/19287/abstract/34\">",
"       34",
"      </a>",
"      ]. The pregnancy was allowed to continue and BEP was not initiated until after the baby was delivered at 36 weeks. At a follow-up of 27 months, there was no evidence of recurrence disease.",
"     </li>",
"     <li>",
"      Another report described a patient with a yolk sac tumor resected at 22 weeks of gestation, after which the pregnancy was allowed to continue [",
"      <a class=\"abstract\" href=\"UTD.htm?18/53/19287/abstract/35\">",
"       35",
"      </a>",
"      ]. Unfortunately, at 34 weeks she was found to have tumor regrowth. After secondary debulking and delivery of the infant, the mother was successfully treated with BEP and was without evidence of disease 39 months after her last treatment with chemotherapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These reports suggest that delaying adjuvant chemotherapy may increase the risk of recurrence, although without an apparent risk to long-term recurrence free survival. Given the low quality of the data, however, a decision on the timing of adjuvant chemotherapy for women with a germ cell tumor should take into account the individual circumstances and preferences of the mother.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     TUMORS OF LOW MALIGNANT POTENTIAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tumors of low malignant potential have an excellent prognosis and management is the same as that for non-pregnant patients [",
"    <a class=\"abstract\" href=\"UTD.htm?18/53/19287/abstract/37\">",
"     37",
"    </a>",
"    ]. In general, treatment is surgical and most patients do not require adjuvant chemotherapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/0/5128?source=see_link\">",
"     \"Ovarian tumors of low malignant potential\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SEX CORD-STROMAL TUMORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most of these tumors are limited to one ovary, of low malignant potential",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    slowly progressive. The benefit of postoperative treatment for women with stage 1B to IV disease (",
"    <a class=\"graphic graphic_table graphicRef51205 \" href=\"UTD.htm?14/43/15038\">",
"     table 1",
"    </a>",
"    ) is unclear and practice is variable. Therefore, we suggest oophorectomy alone for disease diagnosed during pregnancy. The decision for chemotherapy, if any, can be deferred to the postpartum period. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/36/8778?source=see_link\">",
"     \"Sex cord-stromal tumors of the ovary: Granulosa-stromal cell tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The development of a gynecologic cancer during pregnancy is a rare event, affecting less than one in 10,000 pregnancies. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The risks of chemotherapy administration during pregnancy depend on the specific drugs used and the gestational age of the fetus. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'General principles'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Early delivery to avoid fetal exposure to chemotherapy is reasonable provided the fetus is &ge;34 weeks of gestation",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      fetal lung maturity can be documented. In this setting, the risks of prematurity are relatively low. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/41/4759?source=see_link&amp;anchor=H8#H8\">",
"       \"Management of ovarian cancer in pregnant women\", section on 'Chemotherapy and timing of delivery'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      If chemotherapy is indicated, we recommend instituting platinum-based chemotherapy during pregnancy rather than waiting until after delivery (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). We recommend delaying administration until at least the second trimester in order to minimize the potential for fetal injury (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'General principles'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women with epithelial ovarian cancer in pregnancy, we recommend platinum-based therapy (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Patients should be informed of the limited data on maternal and fetal outcomes associated with platinum",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      taxane therapy.",
"     </li>",
"     <li>",
"      For most women with germ cell tumors, we recommend adjuvant platinum-based combination chemotherapy (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). &nbsp;However, women with stage IA dysgerminomas or stage I grade 1 immature teratomas have a good prognosis. We recommend not treating these patients with chemotherapy (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/24/33162?source=see_link\">",
"       \"Treatment of malignant germ cell tumors of the ovary\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Oophorectomy is the standard treatment for tumors of low malignant potential and sex cord stromal tumors diagnosed during pregnancy. These patients should not receive chemotherapy in pregnancy. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Sex cord-stromal tumors'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/53/19287/abstract/1\">",
"      Amant F, Brepoels L, Halaska MJ, et al. Gynaecologic cancer complicating pregnancy: an overview. Best Pract Res Clin Obstet Gynaecol 2010; 24:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/53/19287/abstract/2\">",
"      Zhao XY, Huang HF, Lian LJ, Lang JH. Ovarian cancer in pregnancy: a clinicopathologic analysis of 22 cases and review of the literature. Int J Gynecol Cancer 2006; 16:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/53/19287/abstract/3\">",
"      Behtash N, Karimi Zarchi M, Modares Gilani M, et al. Ovarian carcinoma associated with pregnancy: a clinicopathologic analysis of 23 cases and review of the literature. BMC Pregnancy Childbirth 2008; 8:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/53/19287/abstract/4\">",
"      Whitecar MP, Turner S, Higby MK. Adnexal masses in pregnancy: a review of 130 cases undergoing surgical management. Am J Obstet Gynecol 1999; 181:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/53/19287/abstract/5\">",
"      Cardonick E, Iacobucci A. Use of chemotherapy during human pregnancy. Lancet Oncol 2004; 5:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/53/19287/abstract/6\">",
"      Theriault R, Hahn K. Management of breast cancer in pregnancy. Curr Oncol Rep 2007; 9:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/53/19287/abstract/7\">",
"      Nicholson HO. Cytotoxic drugs in pregnancy. Review of reported cases. J Obstet Gynaecol Br Commonw 1968; 75:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/53/19287/abstract/8\">",
"      Doll DC, Ringenberg QS, Yarbro JW. Management of cancer during pregnancy. Arch Intern Med 1988; 148:2058.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/53/19287/abstract/9\">",
"      Leslie KK, Koil C, Rayburn WF. Chemotherapeutic drugs in pregnancy. Obstet Gynecol Clin North Am 2005; 32:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/53/19287/abstract/10\">",
"      Ebert U, L&ouml;ffler H, Kirch W. Cytotoxic therapy and pregnancy. Pharmacol Ther 1997; 74:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/53/19287/abstract/11\">",
"      Boulay R, Podczaski E. Ovarian cancer complicating pregnancy. Obstet Gynecol Clin North Am 1998; 25:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/53/19287/abstract/12\">",
"      Zagouri F, Sergentanis TN, Chrysikos D, et al. Taxanes for ovarian cancer during pregnancy: a systematic review. Oncology 2012; 83:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/53/19287/abstract/13\">",
"      Mir O, Berveiller P, Goffinet F, et al. Taxanes for breast cancer during pregnancy: a systematic review. Ann Oncol 2010; 21:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/53/19287/abstract/14\">",
"      M&eacute;ndez LE, Mueller A, Salom E, Gonz&aacute;lez-Quintero VH. Paclitaxel and carboplatin chemotherapy administered during pregnancy for advanced epithelial ovarian cancer. Obstet Gynecol 2003; 102:1200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/53/19287/abstract/15\">",
"      Picone O, Lhomm&eacute; C, Tournaire M, et al. Preservation of pregnancy in a patient with a stage IIIB ovarian epithelial carcinoma diagnosed at 22 weeks of gestation and treated with initial chemotherapy: case report and literature review. Gynecol Oncol 2004; 94:600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/53/19287/abstract/16\">",
"      Sood AK, Shahin MS, Sorosky JI. Paclitaxel and platinum chemotherapy for ovarian carcinoma during pregnancy. Gynecol Oncol 2001; 83:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/53/19287/abstract/17\">",
"      Ferrandina G, Distefano M, Testa A, et al. Management of an advanced ovarian cancer at 15 weeks of gestation: case report and literature review. Gynecol Oncol 2005; 97:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/53/19287/abstract/18\">",
"      Tomlinson MW, Treadwell MC, Deppe G. Platinum based chemotherapy to treat recurrent Sertoli-Leydig cell ovarian carcinoma during pregnancy. Eur J Gynaecol Oncol 1997; 18:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/53/19287/abstract/19\">",
"      Sayedur Rahman M, Al-Sibai MH, Rahman J, et al. Ovarian carcinoma associated with pregnancy. A review of 9 cases. Acta Obstet Gynecol Scand 2002; 81:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/53/19287/abstract/20\">",
"      Huang HP, Fang CN, Kan YY. Chemotherapy for ovarian mucinous cystadenocarcinoma during pregnancy: a case report. Eur J Gynaecol Oncol 2004; 25:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/53/19287/abstract/21\">",
"      Raffles A, Williams J, Costeloe K, Clark P. Transplacental effects of maternal cancer chemotherapy. Case report. Br J Obstet Gynaecol 1989; 96:1099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/53/19287/abstract/22\">",
"      Henderson CE, Elia G, Garfinkel D, et al. Platinum chemotherapy during pregnancy for serous cystadenocarcinoma of the ovary. Gynecol Oncol 1993; 49:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/53/19287/abstract/23\">",
"      Modares Gilani M, Karimi Zarchi M, Behtash N, et al. Preservation of pregnancy in a patient with advanced ovarian cancer at 20 weeks of gestation: case report and literature review. Int J Gynecol Cancer 2007; 17:1140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/53/19287/abstract/24\">",
"      Tabata T, Nishiura K, Tanida K, et al. Carboplatin chemotherapy in a pregnant patient with undifferentiated ovarian carcinoma: case report and review of the literature. Int J Gynecol Cancer 2008; 18:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/53/19287/abstract/25\">",
"      Mir O, Berveiller P, Ropert S, et al. Use of platinum derivatives during pregnancy. Cancer 2008; 113:3069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/53/19287/abstract/26\">",
"      Doi D, Boh Y, Konishi H, et al. Combined chemotherapy with paclitaxel and carboplatin for mucinous cystadenocarcinoma of the ovary during pregnancy. Arch Gynecol Obstet 2009; 280:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/53/19287/abstract/27\">",
"      Machado F, Vegas C, Leon J, et al. Ovarian cancer during pregnancy: analysis of 15 cases. Gynecol Oncol 2007; 105:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/53/19287/abstract/28\">",
"      Cardonick E, Bhat A, Gilmandyar D, Somer R. Maternal and fetal outcomes of taxane chemotherapy in breast and ovarian cancer during pregnancy: case series and review of the literature. Ann Oncol 2012; 23:3016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/53/19287/abstract/29\">",
"      Bolis G, Colombo N, Pecorelli S, et al. Adjuvant treatment for early epithelial ovarian cancer: results of two randomised clinical trials comparing cisplatin to no further treatment or chromic phosphate (32P). G.I.C.O.G.: Gruppo Interregionale Collaborativo in Ginecologia Oncologica. Ann Oncol 1995; 6:887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/53/19287/abstract/30\">",
"      Katsumata N, Yasuda M, Takahashi F, et al. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet 2009; 374:1331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/53/19287/abstract/31\">",
"      Hubalek M, Smekal-Schindelwig C, Zeimet AG, et al. Chemotherapeutic treatment of a pregnant patient with ovarian dysgerminoma. Arch Gynecol Obstet 2007; 276:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/53/19287/abstract/32\">",
"      Elit L, Bocking A, Kenyon C, Natale R. An endodermal sinus tumor diagnosed in pregnancy: case report and review of the literature. Gynecol Oncol 1999; 72:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/53/19287/abstract/33\">",
"      Robova H, Rob L, Hrehorcak M, et al. Endodermal sinus tumor diagnosed in pregnancy: a case report. Int J Gynecol Cancer 2007; 17:914.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/53/19287/abstract/34\">",
"      Shimizu Y, Komiyama S, Kobayashi T, et al. Successful management of endodermal sinus tumor of the ovary associated with pregnancy. Gynecol Oncol 2003; 88:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/53/19287/abstract/35\">",
"      Aoki Y, Higashino M, Ishii S, Tanaka K. Yolk sac tumor of the ovary during pregnancy: a case report. Gynecol Oncol 2005; 99:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/53/19287/abstract/36\">",
"      Rajendran S, Hollingworth J, Scudamore I. Endodermal sinus tumour of the ovary in pregnancy. Eur J Gynaecol Oncol 1999; 20:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/53/19287/abstract/37\">",
"      Morice P, Uzan C, Gouy S, et al. Gynaecological cancers in pregnancy. Lancet 2012; 379:558.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3198 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-79.122.249.114-59E8FFCE15-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_53_19287=[""].join("\n");
var outline_f18_53_19287=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENERAL PRINCIPLES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27955600\">",
"      Multiagent versus single agent chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27955677\">",
"      Treatment during first trimester versus later",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      OVARIAN CANCER DURING PREGNANCY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H84410292\">",
"      EPITHELIAL OVARIAN CANCER",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Indications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H294838285\">",
"      Regimen",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H294838014\">",
"      - Platinum",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H294838021\">",
"      - Taxanes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H294839653\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H294839610\">",
"      - Intraperitoneal (IP) therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H294838311\">",
"      Timing of chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H294838341\">",
"      - Early stage disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H294838374\">",
"      - Advanced stage disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      GERM CELL TUMORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Timing of chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      TUMORS OF LOW MALIGNANT POTENTIAL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SEX CORD-STROMAL TUMORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/3198\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/3198|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/43/15038\" title=\"table 1\">",
"      Staging ovarian peritoneal carcinoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/2/14382\" title=\"table 2\">",
"      Bleomycin etoposide and cisplatin regimen",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/39/26231?source=related_link\">",
"      Adjuvant therapy of early stage (stage I and II) epithelial ovarian, fallopian tubal, or peritoneal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/62/9192?source=related_link\">",
"      Clinical manifestations and diagnosis of ovarian cancer in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/11/21689?source=related_link\">",
"      First-line chemotherapy for advanced (stage III or IV) epithelial ovarian, fallopian tubal, and peritoneal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/41/4759?source=related_link\">",
"      Management of ovarian cancer in pregnant women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/37/5721?source=related_link\">",
"      Ovarian germ cell neoplasms: Pathology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/0/5128?source=related_link\">",
"      Ovarian tumors of low malignant potential",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/36/8778?source=related_link\">",
"      Sex cord-stromal tumors of the ovary: Granulosa-stromal cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/33/38425?source=related_link\">",
"      Surgical management of advanced testicular germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/24/33162?source=related_link\">",
"      Treatment of malignant germ cell tumors of the ovary",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_53_19288="Malaria life cycle drug targets";
var content_f18_53_19288=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F79113&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F79113&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 562px\">",
"   <div class=\"ttl\">",
"    Life cycle of Plasmodium*",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 542px; height: 579px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    1. Plasmodium-infected Anopheles mosquito bites a human and transmits sporozoites into the bloodstream. 2. Sporozoites migrate through the blood to the liver where they invade hepatocytes and divide to form multinucleated schizonts (pre-erythrocytic stage). Atovaquone-proguanil and primaquine have activity against hepatic-stage schizonts. 3. Hypnozoites are a quiescent stage in the liver that exist only in the setting of P. vivax and P. ovale infection. This liver stage does not cause clinical symptoms, but with reactivation and release into the circulation, late-onset or relapsed disease can occur up to many months after initial infection. Primaquine is active against the quiescent hypnozoites of P. vivax and P. ovale. 4. The schizonts rupture and release merozoites into the circulation where they invade red blood cells. Within red cells, merozoites mature from ring forms to trophozoites to multinucleated schizonts (erythrocytic stage). Blood-stage schizonticides interrupt schizogony within red cells. 5. Some merozoites differentiate into male or female gametocytes. These cells are ingested by the Anopheles mosquito and mature in the midgut, where sporozoites develop and migrate to the salivary glands of the mosquito. The mosquito completes the cycle of transmission by biting another host.",
"    <div class=\"footnotes\">",
"     * There is strong evidence that drugs listed in parentheses are active against designated stage of parasitic life cycle.",
"     <br>",
"      &bull; Quinoline derivatives are blood stage schizonticides with the exception of primaquine.",
"      <br>",
"       &Delta; Primaquine is a blood stage schizonticide with activity against schizonts of P. vivax but not those of P. falciparum. Quinoline derivatives include chloroquine, amodiaquine, quinine, quinidine, mefloquine, primaquine, lumefantrine and halofantrine. Antifolates include sulfadoxine-pyrimethamine and atovaquone-proguanil. Antimicrobials include tetracycline, doxycycline and clindamycin.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_53_19288=[""].join("\n");
var outline_f18_53_19288=null;
var title_f18_53_19289="Clonidine: Drug information";
var content_f18_53_19289=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Clonidine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?20/7/20598?source=see_link\">",
"    see \"Clonidine: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/14/13545?source=see_link\">",
"    see \"Clonidine: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708678\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F153485\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Catapres-TTS&reg;-1;",
"     </li>",
"     <li>",
"      Catapres-TTS&reg;-2;",
"     </li>",
"     <li>",
"      Catapres-TTS&reg;-3;",
"     </li>",
"     <li>",
"      Catapres&reg;;",
"     </li>",
"     <li>",
"      Duraclon&reg;;",
"     </li>",
"     <li>",
"      Kapvay&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F153486\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Clonidine&reg;;",
"     </li>",
"     <li>",
"      Catapres&reg;;",
"     </li>",
"     <li>",
"      Dixarit&reg;;",
"     </li>",
"     <li>",
"      Dom-Clonidine;",
"     </li>",
"     <li>",
"      Novo-Clonidine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F153534\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Alpha",
"      <sub>",
"       2",
"      </sub>",
"      -Adrenergic Agonist",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F153489\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Dosing is expressed as the salt (clonidine hydrochloride) unless otherwise noted. Formulations of clonidine (immediate release versus extended release) are not interchangeable on a mg:mg basis due to different pharmacokinetic profiles.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Hypertension:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: Immediate release: Initial dose: 0.1 mg twice daily (maximum recommended dose: 2.4 mg/day); usual dose range (JNC 7): 0.1-0.8 mg/day in 2 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Transdermal: Initial: 0.1 mg/24 hour patch applied once every 7 days and increase by 0.1 mg at 1- to 2-week intervals (dosages &gt;0.6 mg/24 hours do not improve efficacy); usual dose range (JNC 7): 0.1-0.3 mg/24 hour patch applied applied once every 7 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Acute hypertension (urgency) (unlabeled use):",
"     </b>",
"     Oral: Initial 0.1-0.2 mg; may be followed by additional doses of 0.1 mg every hour, if necessary, to a maximum total dose of 0.7 mg (Atkin, 1992; Jaker, 1989)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Unlabeled route of administration: Sublingual: Initial: 0.1-0.2 mg; followed by 0.05-0.1 mg every hour until blood pressure controlled or a cumulative dose of 0.7 mg is reached (Cunningham, 1994; Matuschka, 1999)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Nicotine withdrawal symptoms (unlabeled use; Fiore, 2008):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: Initial: 0.1 mg twice daily; titrate by 0.1 mg/day every 7 days if needed; dosage range used in clinical trials: 0.15-0.75 mg/day; duration of therapy ranged from 3-10 weeks in clinical trials",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Transdermal: Initial: 0.1 mg/24 hour patch applied once every 7 days and increase by 0.1 mg at 1-week intervals if necessary; dosage range used in clinical trials: 0.1-0.2 mg/24 hour patch applied once every 7 days; duration of therapy ranged from 3-10 weeks in clinical trials",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Pain management:",
"     </b>",
"     Epidural infusion: Reserved for cancer patients with severe intractable pain, unresponsive to other opioid analgesics: Starting dose: 30 mcg/hour; titrate as required for relief of pain or presence of side effects; experience with doses &gt;40 mcg/hour is limited; should be considered an adjunct to opioid therapy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <i>",
"      Conversion from oral to transdermal:",
"     </i>",
"     <b>",
"      Note:",
"     </b>",
"     If transitioning from oral to transdermal therapy, overlap oral regimen for 1-2 days; transdermal route takes 2-3 days to achieve therapeutic effects. An example transition is below:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Day 1: Place Catapres-TTS&reg; 1; administer 100% of oral dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Day 2: Administer 50% of oral dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Day 3: Administer 25% of oral dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Day 4: Patch remains, no further oral supplement necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Conversion from transdermal to oral:",
"     </i>",
"     After transdermal patch removal, therapeutic clonidine levels persist for ~8 hours and then slowly decrease over several days. Consider starting oral clonidine no sooner than 8 hours after patch removal.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F153510\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/14/13545?source=see_link\">",
"      see \"Clonidine: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Dosing is expressed as the salt (clonidine hydrochloride) unless otherwise noted. Formulations of clonidine (immediate release versus extended release) are not interchangeable on a mg:mg basis due to different pharmacokinetic profiles.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Hypertension (unlabeled use):",
"     </b>",
"     Oral: Children &ge;12 years: Immediate release: Initial: 0.2 mg/day in 2 divided doses; increase gradually, if needed, in 0.1 mg/day increments at weekly intervals; maximum: 2.4 mg/day (rarely required) (NHBPEP, Fourth Report)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Severe hypertension (unlabeled use):",
"     </b>",
"     Oral: Children: Immediate release: 0.05-0.1 mg/dose; may repeat up to a maximum total dose of 0.8 mg (NHBPEP, Fourth Report)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Clonidine tolerance test (test of growth hormone release from pituitary) (unlabeled use):",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.15 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     as a single dose (Lanes, 1982)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      or",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mcg/kg as a single dose; maximum dose: 250 mcg (Richmond, 2008)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      ADHD:",
"     </b>",
"     Oral:",
"     <b>",
"      Note:",
"     </b>",
"     May be used alone or as an adjunct to stimulants.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Immediate release",
"     </i>",
"     (unlabeled indication; Pliszka, 2007):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children &le;45 kg: Initial: 0.05 mg at bedtime; sequentially increase every 3-7 days by 0.05 mg increments as twice daily, then 3 times daily, then 4 times daily; maximum daily dose: 0.2 mg/day for patients weighing 27-40.5 kg; 0.3 mg/day for patients weighing 40.5-45 kg. When discontinuing therapy, taper gradually over 1-2 weeks.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children &gt;45 kg: Initial: 0.1 mg at bedtime; sequentially increase every 3-7 days by 0.1 mg increments as twice daily, then 3 times daily, then 4 times daily; maximum daily dose: 0.4 mg/day. When discontinuing therapy, taper gradually over 1-2 weeks.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Extended release (Kapvay&trade;):",
"     </i>",
"     Children &ge;6 years: Initial: 0.1 mg at bedtime; increase in 0.1 mg/day increments every 7 days until desired response, doses should be administered twice daily (either split equally or with the higher split dosage given at bedtime); maximum: 0.4 mg/day.",
"     <b>",
"      Note:",
"     </b>",
"     Maintenance treatment for &gt;5 weeks has not been evaluated. When discontinuing therapy, taper daily dose by &le;0.1 mg every 3-7 days.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Pain management:",
"     </b>",
"     Epidural infusion: Reserved for cancer patients with severe intractable pain, unresponsive to other opioid analgesics: Initial: 0.5 mcg/kg/",
"     <b>",
"      hour",
"     </b>",
"     ; adjust with caution, based on clinical effect",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F153490\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Hypertension:",
"     </b>",
"     Oral: Immediate release: Initial: 0.1 mg once daily at bedtime, increase gradually as needed.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F153491\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Children: Oral (extended release), epidural: The manufacturer recommends dosage adjustment according to degree of renal impairment; however, no specific dosage adjustment provided (has not been studied).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Adults: Oral (immediate release), transdermal, epidural: The manufacturer recommends dosage adjustment according to degree of renal impairment; however, no specific dosage adjustment provided in manufacturer&rsquo;s labeling. Bradycardia, sedation, and hypotension may be more likely to occur in patients with renal failure; half-life significantly prolonged in patients with severe renal failure; consider use of lower initial doses and monitor closely.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hemodialysis: Not dialyzable (0% to 5%); supplemental dose is not necessary. Oral antihypertensive drugs given preferentially at night may reduce the nocturnal surge of blood pressure and minimize the intradialytic hypotension that may occur when taken the morning before a dialysis session (K/DOQI, 2005).",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15795877\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F153455\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as hydrochloride [epidural, preservative free]: 100 mcg/mL (10 mL); 500 mcg/mL (10 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Duraclon&reg;: 100 mcg/mL (10 mL); 500 mcg/mL (10 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Patch, transdermal: 0.1 mg/24 hours (4s); 0.2 mg/24 hours (4s); 0.3 mg/24 hours (4s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Catapres-TTS&reg;-1: 0.1 mg/24 hours (4s) [contains metal]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Catapres-TTS&reg;-2: 0.2 mg/24 hours (4s) [contains metal]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Catapres-TTS&reg;-3: 0.3 mg/24 hours (4s) [contains metal]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as hydrochloride: 0.1 mg, 0.2 mg, 0.3 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Catapres&reg;: 0.1 mg, 0.2 mg, 0.3 mg [scored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, extended release, oral, as hydrochloride:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Kapvay&reg;: 0.1 mg, 0.2 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, extended release, oral, as hydrochloride [dose-pack]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Kapvay&reg;: 0.1 mg AM dose, 0.2 mg PM dose",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F153441\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes extended release tablets",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F153460\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Epidural: Specialized techniques are required for continuous epidural administration; administration via this route should only be performed by qualified individuals familiar with the techniques of epidural administration and patient management problems associated with this route. Familiarization of the epidural infusion device is essential. Do not discontinue clonidine abruptly; if needed, gradually reduce dose over 2-4 days to avoid withdrawal symptoms.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: May be taken with or without food. Do not discontinue clonidine abruptly. If needed, gradually reduce dose over 2-4 days to avoid rebound hypertension.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Extended release tablet: Kapvay&trade;: Swallow whole; do not crush, split, or chew.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Transdermal patch: Patches should be applied weekly at a consistent time to a clean, hairless area of the upper outer arm or chest. Rotate patch sites weekly. Redness under patch may be reduced if a topical corticosteroid spray is applied to the area before placement of the patch (Tom, 1994).",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F153541\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in NS",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Note:",
"     </b>",
"     Epidural formulation is",
"     <b>",
"      NOT",
"     </b>",
"     for I.V. administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Aminophylline, dobutamine, dopamine, epinephrine, fentanyl, labetalol, lorazepam, magnesium sulfate, nitroglycerin, norepinephrine, potassium chloride, theophylline, verapamil.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Midazolam.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Bupivacaine, bupivacaine with fentanyl, bupivacaine with morphine, fentanyl, fentanyl with lidocaine, heparin, ketamine with tetracaine, lidocaine, tetracaine, ziconotide.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Morphine.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F153459\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Immediate release: Management of  hypertension (monotherapy or as adjunctive therapy)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Extended release (Kapvay&trade;): Treatment of attention-deficit/hyperactivity disorder (ADHD) (monotherapy or as adjunctive therapy)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Epidural (Duraclon&reg;): For continuous epidural administration as adjunctive therapy with opioids for treatment of severe cancer pain in patients tolerant to or unresponsive to opioids alone; epidural clonidine is generally more effective for neuropathic pain and less effective (or possibly ineffective) for somatic or visceral pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Transdermal patch: Management of hypertension (monotherapy or as adjunctive therapy)",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F153530\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Heroin or nicotine withdrawal; severe pain; dysmenorrhea; vasomotor symptoms associated with menopause; ethanol dependence; prophylaxis of migraines; glaucoma; diabetes-associated diarrhea; impulse control disorder, clozapine-induced sialorrhea; aid in the diagnosis of growth hormone deficiency; attention-deficit/hyperactivity disorder (ADHD) and associated insomnia in children; Tourette's syndrome in children; aggression associated with conduct disorder",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F153543\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       CloNIDine may be confused with Clomid&reg;, clomiPHENE, clonazePAM, cloZAPine, KlonoPIN&reg;, quiNIDine",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Catapres&reg; may be confused with Cataflam&reg;, Combipres",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication (epidural administration) among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - low; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Administration issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Use caution when interpreting dosing information. Pediatric dose for epidural infusion expressed as mcg/kg/",
"       <b>",
"        hour",
"       </b>",
"       .",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Transdermal patch may contain conducting metal (eg, aluminum); remove patch prior to MRI. Errors have occurred when the inactive, optional adhesive cover has been applied instead of the active clonidine-containing patch.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F153532\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not always defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Oral, Transdermal:",
"     </b>",
"     Incidence of adverse events may be less with transdermal compared to oral due to the lower peak/trough ratio.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Cardiovascular:  Bradycardia (&le;4%), palpitation (1%), tachycardia (1%), arrhythmia, atrioventricular block, chest pain, CHF, ECG abnormalities, flushing, orthostatic hypotension, pallor, Raynaud&rsquo;s phenomenon, syncope",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Drowsiness (12% to 38%), headache (1% to 29%), fatigue (4% to 16%), dizziness (2% to 16%), sedation (3% to 10%), insomnia (&le;6%), lethargy (3%), nervousness (1% to 3%), mental depression (1%), aggression, agitation, anxiety, behavioral changes, CVA, delirium, delusional perception, fever, hallucinations (visual and auditory), irritability, malaise, nightmares, restlessness, vivid dreams",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Transient localized skin reactions characterized by pruritus and erythema (transdermal 15% to 50%), contact dermatitis (transdermal 8% to 34%), vesiculation (transdermal 7%), allergic contact sensitization (transdermal 5%), hyperpigmentation (transdermal 5%), burning (transdermal 3%), edema (3%), excoriation (transdermal 3%) blanching (transdermal 1%), generalized macular rash (1%), papules (transdermal 1%), throbbing (transdermal 1%), alopecia, angioedema, hives, localized hypopigmentation (transdermal), rash, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Sexual dysfunction (3%), gynecomastia (1%), creatine phosphokinase increased (transient; oral), hyperglycemia (transient; oral), libido decreased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Xerostomia (&le;40%), constipation (2% to 10%), anorexia (1%), taste perversion (1%), weight gain (&lt;1%), abdominal pain (oral), diarrhea, nausea, parotid gland pain (oral), parotitis (oral), pseudo-obstruction (oral), throat pain, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary:  Erectile dysfunction (2% to 3%), nocturia (1%), dysuria, enuresis, urinary retention",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Thrombocytopenia (oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Liver function test (mild transient abnormalities; &le;1%), hepatitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness (10%), arthralgia (1%), myalgia (1%), leg cramps (&lt;1%), numbness (localized, transdermal), pain in extremities, paresthesia, tremor",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Accommodation disorder, blurred vision, burning eyes, dry eyes, lacrimation decreased, lacrimation increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Otic: Ear pain, otitis media",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Pollakiuria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Asthma, epistaxis, nasal congestion, nasal dryness, nasopharyngitis, respiratory tract infection, rhinorrhea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Withdrawal syndrome (1%), flu-like syndrome, thirst",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Epidural:",
"     </b>",
"     <b>",
"      Note:",
"     </b>",
"     The following adverse events occurred more often than placebo in cancer patients with intractable pain being treated with concurrent epidural morphine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Hypotension (45%), orthostatic hypotension (32%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Confusion (13%), dizziness (13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Xerostomia (13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Chest pain (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Hallucinations (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea/vomiting (8%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Otic: Tinnitus (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis (5%)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F153463\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to clonidine hydrochloride or any component of the formulation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     Epidural administration: Injection site infection; concurrent anticoagulant therapy; bleeding diathesis; administration above the C4 dermatome",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F153445\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bradycardia: May cause dose-dependent reductions in heart rate; use with caution in patients with preexisting bradycardia or those predisposed to developing bradycardia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypotension: Symptomatic hypotension may occur with use. In all patients, use epidural clonidine with caution due to the potential for severe hypotension, especially in women and those of low body weight. Most hypotensive episodes occur within the first 4 days of initiation; however, episodes may occur throughout the duration of therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Respiratory depression: Epidural administration may result in mild respiratory depression (usually associated with higher than recommended doses).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Xerostomia: May cause significant xerostomia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with severe coronary insufficiency, including recent MI and conduction disturbances, including sinus node dysfunction. The use of epidural clonidine frequently reduces heart rate; AV block greater than first-degree has been reported rarely. Epidural clonidine is not recommended for use in patients with severe cardiovascular disease or hemodynamic instability. May lead to cardiovascular instability (hypotension, bradycardia).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cerebrovascular disease:  Use with caution in patients with cerebrovascular disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with chronic renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Agents with SA/AV nodal blocking properties: Use with caution in patients concurrently receiving agents known to reduce SA node function and/or AV nodal conduction (eg, digoxin, diltiazem, metoprolol, verapamil); may increase risk of serious bradycardia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depressants: Sedating effects may be potentiated when used with other CNS-depressant drugs or ethanol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Avoid use as first-line antihypertensive due to high risk of CNS adverse effects; may also cause orthostatic hypotension and bradycardia (Beers Criteria).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Since children commonly have gastrointestinal illnesses with vomiting, they are susceptible to hypertensive episodes due to abrupt inability to take oral medication. Epidural clonidine should be reserved for pediatric cancer patients with severe intractable pain, unresponsive to other analgesics or epidural or spinal opioids.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Surgical patients: Discontinue oral immediate release formulations within 4 hours of surgery then restart as soon as possible afterwards. Discontinue oral extended release formulations up to 28 hours prior to surgery, then restart the following day.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Epidural use:",
"     <b>",
"      [U.S. Boxed Warning]: Must dilute concentrated epidural injectable (500 mcg/mL) solution prior to use.  Epidural clonidine is not recommended for perioperative, obstetrical, or postpartum pain due to risk of hemodynamic instability.",
"     </b>",
"     Should be administered via continuous epidural infusion device. Monitor closely for catheter-related infection such as meningitis or epidural abscess.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Product interchangeability: Oral formulations of clonidine (immediate release versus extended release) are not interchangeable on a mg:mg basis due to different pharmacokinetic profiles.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Transdermal patch: May contain conducting metal (eg, aluminum); remove patch prior to MRI. Due to the  potential for altered electrical conductivity, remove transdermal patch before cardioversion or defibrillation. Localized contact sensitization to the transdermal system has been reported; in these patients, allergic reactions (eg, generalized rash, urticaria, angioedema) have also occurred following subsequent substitution of oral therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Contact lens wearers:  Clonidine may cause eye dryness in patients who wear contact lenses.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Discontinuation of therapy: Gradual withdrawal is needed (taper oral immediate release or epidural dose  gradually over 2-4 days to avoid rebound hypertension) if drug needs to be stopped. Patients should be instructed about abrupt discontinuation (causes rapid increase in BP and symptoms of sympathetic overactivity). In patients on both a beta-blocker and clonidine where withdrawal of clonidine is necessary, withdraw the beta-blocker first and several days before clonidine withdrawal, then slowly decrease clonidine. In children and adolescents, extended release formulation (Kapvay&trade;) should be tapered in decrements of no more than 0.1 mg every 3-7 days.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299067\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F153450\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfuzosin: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amifostine: Antihypertensives may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, antihypertensive medications should be withheld for 24 hours prior to amifostine administration. If antihypertensive therapy can not be withheld, amifostine should not be administered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidepressants (Alpha2-Antagonist): May diminish the antihypertensive effect of Alpha2-Agonists. Management: Consider avoiding concurrent use.  If these combinations cannot be avoided, monitor for decreased effects of alpha2-agonists if an alpha2-antagonist is initiated/dose increased, or increased effects if an alpha2-antagonist is discontinued/dose decreased.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: May enhance the hypotensive effect of other Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: Alpha2-Agonists may enhance the AV-blocking effect of Beta-Blockers. Sinus node dysfunction may also be enhanced. Beta-Blockers may enhance the rebound hypertensive effect of Alpha2-Agonists. This effect can occur when the alpha",
"     <sub>",
"      2",
"     </sub>",
"     -agonist is abruptly withdrawn.  Management: Closely monitor heart rate during treatment with a beta blocker and clonidine. Withdraw beta blockers several days before clonidine withdrawal when possible, and monitor blood pressure closely. Recommendations for other alpha2-agonists are unavailable.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levobunolol; Metipranolol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Nondihydropyridine): CloNIDine may enhance the AV-blocking effect of Calcium Channel Blockers (Nondihydropyridine). Sinus node dysfunction may also be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: CloNIDine may enhance the AV-blocking effect of Cardiac Glycosides. Sinus node dysfunction may also be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diazoxide: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypotensive Properties): May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iobenguane I 123: Alpha2-Agonists may diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May enhance the adverse/toxic effect of CloNIDine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RiTUXimab: Antihypertensives may enhance the hypotensive effect of RiTUXimab.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin/Norepinephrine Reuptake Inhibitors: May diminish the antihypertensive effect of Alpha2-Agonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tricyclic Antidepressants: May diminish the antihypertensive effect of Alpha2-Agonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F153480\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: Avoid ethanol (may increase CNS depression).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Avoid dong quai if using for hypertension (has estrogenic activity). Avoid ephedra, yohimbe, ginseng (may worsen hypertension). Avoid valerian, St John's wort, kava kava, gotu kola (may increase CNS depression).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F153451\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F153467\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have been observed in some animal reproduction studies. Clonidine crosses the placenta; concentrations in the umbilical cord plasma are similar to those in the maternal serum and concentrations in the amniotic fluid may be 4 times those in the maternal serum.",
"     <b>",
"      [U.S. Boxed Warning]: Epidural clonidine is not recommended for obstetrical or postpartum pain",
"     </b>",
"     due to risk of hemodynamic instability.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F153495\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F153468\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk with concentrations approximately twice maternal serum concentrations",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F153466\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid, controlled release",
"     </b>",
"     (Nexiclon XR Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.09 mg/mL (118 mL): $288.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Misc",
"     </b>",
"     (Kapvay Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.1 &amp; 0.2 mg (60): $269.29",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Patch weekly",
"     </b>",
"     (Catapres-TTS-1 Transdermal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.1 mg/24 hrs (4): $196.15",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Patch weekly",
"     </b>",
"     (Catapres-TTS-2 Transdermal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.2 mg/24 hrs (4): $330.26",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Patch weekly",
"     </b>",
"     (Catapres-TTS-3 Transdermal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.3 mg/24 hrs (4): $458.14",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Patch weekly",
"     </b>",
"     (CloNIDine HCl Transdermal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.1 mg/24 hrs (4): $132.49",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.2 mg/24 hrs (4): $223.06",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.3 mg/24 hrs (4): $309.44",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (CloNIDine HCl (Analgesia) Epidural)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mcg/mL (10 mL): $50.40",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mcg/mL (10 mL): $195.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Duraclon Epidural)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mcg/mL (10 mL): $52.80",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mcg/mL (10 mL): $264.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, 12-hour",
"     </b>",
"     (Kapvay Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.1 mg (60): $207.14",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, 24-hour",
"     </b>",
"     (Nexiclon XR Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.17 mg (90): $432.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Catapres Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.1 mg (100): $202.32",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.2 mg (100): $309.53",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.3 mg (100): $388.42",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (CloNIDine HCl Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.1 mg (100): $25.90",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.2 mg (100): $37.55",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.3 mg (100): $52.40",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F153453\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood pressure, standing and sitting/supine, mental status, heart rate",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     When used for the treatment of ADHD, thoroughly evaluate for cardiovascular risk. Monitor heart rate, blood pressure (when started and weaned), and consider obtaining ECG prior to initiation (Vetter, 2008).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Clonidine tolerance test: In addition to growth hormone concentrations, monitor blood pressure and blood glucose (Huang, 2001).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Epidural: Carefully monitor infusion pump; inspect catheter tubing for obstruction or dislodgement to reduce risk of inadvertent abrupt withdrawal of infusion. Monitor closely for catheter-related infection (eg, meningitis or epidural abscess).",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038585\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Arkamin (IN);",
"     </li>",
"     <li>",
"      Aruclonin (HU);",
"     </li>",
"     <li>",
"      Atensina (BR);",
"     </li>",
"     <li>",
"      Catapin (PH);",
"     </li>",
"     <li>",
"      Catapres (AE, AU, BB, BD, BF, BH, BJ, BM, BS, BZ, CI, CL, CY, EG, ET, GB, GH, GM, GN, GY, HK, ID, IE, IL, IN, IQ, IR, JM, JO, JP, KE, KP, KW, LR, MA, ML, MR, MU, MW, MY, NE, NG, NZ, OM, PH, PK, PR, QA, SA, SC, SD, SG, SL, SN, SR, TN, TT, TW, TZ, UG, ZM, ZW);",
"     </li>",
"     <li>",
"      Catapresan (AR, AT, CH, CN, CO, CR, DE, DK, DO, EC, ES, FI, GR, GT, HN, HR, IT, NI, NL, NO, PA, PE, PT, SE, SV, VE);",
"     </li>",
"     <li>",
"      Catapresan Depot (CZ, DE);",
"     </li>",
"     <li>",
"      Catapresan TTS (IT);",
"     </li>",
"     <li>",
"      Catapressan (BE, FR, LU);",
"     </li>",
"     <li>",
"      Chlophazolin (BG);",
"     </li>",
"     <li>",
"      Clonidina Larjan (AR);",
"     </li>",
"     <li>",
"      Clonidural (AR);",
"     </li>",
"     <li>",
"      Clonilou (ES);",
"     </li>",
"     <li>",
"      Clonipresan (PY);",
"     </li>",
"     <li>",
"      Dixarit (LU, NZ);",
"     </li>",
"     <li>",
"      Haemiton (AE, BH, CY, DE, EG, IL, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Hypodine (TH);",
"     </li>",
"     <li>",
"      Iporel (PL);",
"     </li>",
"     <li>",
"      Isoglaucon (ES, HU);",
"     </li>",
"     <li>",
"      Melzin (PH);",
"     </li>",
"     <li>",
"      Menograine (ZA);",
"     </li>",
"     <li>",
"      Normopresan (IL);",
"     </li>",
"     <li>",
"      Normopresin (UY);",
"     </li>",
"     <li>",
"      Paracefan (BE);",
"     </li>",
"     <li>",
"      Winpress (TW)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F153444\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stimulates alpha",
"     <sub>",
"      2",
"     </sub>",
"     -adrenoceptors in the brain stem, thus activating an inhibitory neuron, resulting in reduced sympathetic outflow from the CNS, producing a decrease in peripheral resistance, renal vascular resistance, heart rate, and blood pressure; epidural clonidine may produce pain relief at spinal presynaptic and postjunctional alpha",
"     <sub>",
"      2",
"     </sub>",
"     -adrenoceptors by preventing pain signal transmission; pain relief occurs only for the body regions innervated by the spinal segments where analgesic concentrations of clonidine exist. For the treatment of ADHD, the mechanism of action is unknown; it has been proposed that postsynaptic alpha",
"     <sub>",
"      2",
"     </sub>",
"     -agonist stimulation regulates subcortical activity in the prefrontal cortex, the area of the brain responsible for emotions, attentions, and behaviors and causes reduced hyperactivity, impulsiveness, and distractibility.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F153462\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Oral: Immediate release: 0.5-1 hour (maximum reduction in blood pressure: 2-4 hours); Transdermal: Initial application: 2-3 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: Oral: Immediate release: 6-10 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: Extended release tablets (Kapvay&trade;) are not bioequivalent with immediate release formulations; peak plasma concentrations are 50% lower compared to immediate release formulations",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : Adults: 2.9 L/kg; highly lipid soluble; distributes readily into extravascular sites",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Epidurally administered clonidine readily distributes into plasma via the epidural veins and attains clinically significant systemic concentrations.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 20% to 40%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Extensively hepatic to inactive metabolites; undergoes enterohepatic recirculation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Oral: Immediate release: 70% to 80%; Extended release (Kapvay&trade;): ~89% (relative to immediate release formulation); Transdermal: ~60%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Adults: Normal renal function: 12-16 hours; Renal impairment: Up to 41 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Epidural administration: CSF half-life elimination: 0.8-1.8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Transdermal: Half-life elimination (after patch removal): ~20 hours (due to skin depot effect; increase in plasma clonidine concentrations may occur after patch removal [MacGregor, 1985])",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, plasma: Oral: Immediate release: 1-3 hours; Extended release: 7-8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (40% to 60%as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Atkin SH, Jaker MA, Beaty P, et al, &ldquo;Oral Labetalol Versus Oral Clonidine in the Emergency Treatment of Severe Hypertension,&rdquo;",
"      <i>",
"       Am J Med Sci",
"      </i>",
"      , 1992, 303(1):9-15.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/53/19289/abstract-text/1728876/pubmed\" id=\"1728876\" target=\"_blank\">",
"        1728876",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Geriatrics Society 2012 Beers Criteria Update Expert Panel, \"American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012, 60(4):616-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/53/19289/abstract-text/22376048/pubmed\" id=\"22376048\" target=\"_blank\">",
"        22376048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Capogna G, Celleno D, Zangrillo A, et al, &ldquo;Addition of Clonidine to Epidural Morphine Enhances Postoperative Analgesia After Cesarean Delivery,&rdquo;",
"      <i>",
"       Reg Anesth",
"      </i>",
"      , 1995, 20(1):57-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/53/19289/abstract-text/7727330/pubmed\" id=\"7727330\" target=\"_blank\">",
"        7727330",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chobanian AV, Bakris GL, Black HR, et al, &ldquo;The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2003, 289(19):2560-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/53/19289/abstract-text/12748199/pubmed\" id=\"12748199\" target=\"_blank\">",
"        12748199",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Corazza M, Mantovani L, Virgil A, et al, &ldquo;Allergic Contact Dermatitis From a Clonidine Transdermal Delivery System,&rdquo;",
"      <i>",
"       Contact Dermatitis",
"      </i>",
"      , 1995, 32(4):246.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/53/19289/abstract-text/7600788/pubmed\" id=\"7600788\" target=\"_blank\">",
"        7600788",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cunningham FE, Baughman VL, Peters J, et al, &ldquo;Comparative Pharmacokinetics of Oral versus Sublingual Clonidine,&rdquo;",
"      <i>",
"       J Clin Anesth",
"      </i>",
"      , 1994, 6(5):430-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/53/19289/abstract-text/7986518/pubmed\" id=\"7986518\" target=\"_blank\">",
"        7986518",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fitzgibbon D, Rapp S, Butler S, et al, &ldquo;Rebound Hypertension and Withdrawal Associated With Discontinuation of an Infusion of Epidural Clonidine,&rdquo;",
"      <i>",
"       Anesthesiology",
"      </i>",
"      , 1996, 84(3):729-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/53/19289/abstract-text/8659804/pubmed\" id=\"8659804\" target=\"_blank\">",
"        8659804",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fiore MC, Jaen CR, Baker TB, et al,",
"      <i>",
"       Treating Tobacco Use and Dependence: 2008 Update.",
"      </i>",
"      Clinical Practice Guideline. Rockville, MD: U.S. Department of Health and Human Services. Public Health Service. May 2008. Available at",
"      <a href=\"file://www.surgeongeneral.gov/tobacco/treating_tobacco_use08.pdf\" target=\"_blank\">",
"       file://www.surgeongeneral.gov/tobacco/treating_tobacco_use08.pdf",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hart-Santora D and Hart LL, &ldquo;Clonidine in Attention Deficit Hyperactivity Disorder,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 1992, 26(1):37-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/53/19289/abstract-text/1606344/pubmed\" id=\"1606344\" target=\"_blank\">",
"        1606344",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Huang C, Banergee K, Sochett E, et al, &ldquo;Hypoglycemia Associated With Clonidine Testing for Growth Hormone Deficiency,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 2001, 139(2):323-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/53/19289/abstract-text/11487765/pubmed\" id=\"11487765\" target=\"_blank\">",
"        11487765",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jaker M, Atkin S, Soto M, et al, &ldquo;Oral Nifedipine vs Oral Clonidine in the Treatment of Urgent Hypertension,&rdquo;",
"      <i>",
"       Arch Intern Med",
"      </i>",
"      , 1989, 149(2):260-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/53/19289/abstract-text/2916871/pubmed\" id=\"2916871\" target=\"_blank\">",
"        2916871",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;K/DOQI Clinical Practice Guidelines for Cardiovascular Disease in Dialysis Patients,&rdquo;",
"      <i>",
"       Am J Kidney Dis",
"      </i>",
"      , 2005, 45(4 Suppl 3):46-57. Available at  file://www.kidney.org/professionals/KDOQI/guidelines_cvd/index.htm",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lanes R and Hurtado E, &ldquo;Oral Clonidine - an Effective Growth Hormone-releasing Agent in Prepubertal Subjects,&rdquo;",
"      <i>",
"       J Pediatric",
"      </i>",
"      , 1982, 100(5):710-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/53/19289/abstract-text/7040621/pubmed\" id=\"7040621\" target=\"_blank\">",
"        7040621",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      MacGregor TR, Matzek KM, Keirns JJ, et al, &ldquo;Pharmacokinetics of Transdermally Delivered Clonidine,&rdquo;",
"      <i>",
"       Clin Pharmacol Ther",
"      </i>",
"      , 1985, 38(3):278-84.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/53/19289/abstract-text/4028622/pubmed\" id=\"4028622\" target=\"_blank\">",
"        4028622",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Matuschka PR, &ldquo;Safer Alternatives to Sublingual Nifedipine for the Treatment of Hypertensive Urgencies,&rdquo;",
"      <i>",
"       J Pharm Technol",
"      </i>",
"      , 1999, 15:199-203.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Health and Clinical Excellence (NICE), National Collaborating Centre for Mental Health , &ldquo;Attention Deficit Hyperactivity Disorder, The NICE Guideline on Diagnosis and Management of ADHD in Children, Young People and Adults,&rdquo; National Clinical Practice Guideline Number 72, 2008:1-664. Available at  www.nice.org.uk/cg072",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      NHBPEP (National High Blood Pressure Education Program) Working Group on High Blood Pressure in Children and Adolescents, &ldquo;The Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and Adolescents.&rdquo; Available at",
"      <a href=\"file://www.nhlbi.nih.gov/health/prof/heart/hbp/hbp_ped.pdf\" target=\"_blank\">",
"       file://www.nhlbi.nih.gov/health/prof/heart/hbp/hbp_ped.pdf",
"      </a>",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/53/19289/abstract-text/15286277/pubmed\" id=\"15286277\" target=\"_blank\">",
"        15286277",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pliszka S, &ldquo;Practice Parameter for the Assessment and Treatment of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder,&rdquo;",
"      <i>",
"       J Am Acad Child Adolesc Psychiatry",
"      </i>",
"      , 2007, 46(7):894-921.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/53/19289/abstract-text/17581453/pubmed\" id=\"17581453\" target=\"_blank\">",
"        17581453",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Principles of Analgesic Use in the Treatment of Acute Pain and Cancer Pain,&rdquo; 6th ed, Glenview, IL: American Pain Society, 2008.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Richmond EJ and Rogol AD, &ldquo;Growth Hormone Deficiency in Children,&rdquo;",
"      <i>",
"       Pituitary",
"      </i>",
"      , 2008, 11(2):115-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/53/19289/abstract-text/18425584/pubmed\" id=\"18425584\" target=\"_blank\">",
"        18425584",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rocchini AP, &ldquo;Childhood Hypertension: Etiology, Diagnosis, and Treatment,&rdquo;",
"      <i>",
"       Pediatr Clin North Am",
"      </i>",
"      , 1984, 31(6):1259-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/53/19289/abstract-text/6390314/pubmed\" id=\"6390314\" target=\"_blank\">",
"        6390314",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Scahill L, \"Alpha-2 Adrenergic Agonists in Attention Deficit Hyperactivity Disorder,\"",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 2009, 154(5 Suppl):32-7.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Schmidt GR and Schuna AA, &ldquo;Rebound Hypertension After Discontinuation of Transdermal Clonidine,&rdquo;",
"      <i>",
"       Clin Pharm",
"      </i>",
"      , 1988, 7(10):772-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/53/19289/abstract-text/3233898/pubmed\" id=\"3233898\" target=\"_blank\">",
"        3233898",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sinaiko AR, &ldquo;Pharmacologic Management of Childhood Hypertension,&rdquo;",
"      <i>",
"       Pediatr Clin North Am",
"      </i>",
"      , 1993, 40(1):195-212.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/53/19289/abstract-text/8417406/pubmed\" id=\"8417406\" target=\"_blank\">",
"        8417406",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tom GR and Premer M, \"Hydrocortisone Cream in Clonidine Patch Dermatitis,\"",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 1994, 28(7-8):889-90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/53/19289/abstract-text/7949510/pubmed\" id=\"7949510\" target=\"_blank\">",
"        7949510",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Vetter VL, Elia J, Erickson CH, et al, &ldquo;Cardiovascular Monitoring of Children and Adolescents With Heart Disease Receiving Stimulant Drugs. A Scientific Statement from the American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee and the Council on Cardiovascular Nursing,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2008, 117:2407-23.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/53/19289/abstract-text/18427125/pubmed\" id=\"18427125\" target=\"_blank\">",
"        18427125",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9285 Version 47.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-122.72.76.133-87E6A227E7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_53_19289=[""].join("\n");
var outline_f18_53_19289=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708678\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153485\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153486\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153534\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153489\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153510\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153490\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153491\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15795877\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153455\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153441\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153460\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153541\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153459\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153530\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153543\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153532\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153463\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153445\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299067\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153450\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153480\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153451\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153467\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153495\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153468\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153466\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153453\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038585\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153444\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153462\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9285\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9285|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?20/7/20598?source=related_link\">",
"      Clonidine: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/14/13545?source=related_link\">",
"      Clonidine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_53_19290="Acute kidney injury in children: Clinical features, etiology, evaluation, and diagnosis";
var content_f18_53_19290=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Acute kidney injury in children: Clinical features, etiology, evaluation, and diagnosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/53/19290/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/53/19290/contributors\">",
"     Prasad Devarajan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/53/19290/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/53/19290/contributors\">",
"     Tej K Mattoo, MD, DCH, FRCP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/53/19290/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/53/19290/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?18/53/19290/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 1, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H17605554\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute kidney injury (AKI) is defined as the abrupt loss of kidney function that results in a decline in glomerular filtration rate (GFR), retention of urea and other nitrogenous waste products, and dysregulation of extracellular volume and electrolytes. The term AKI has largely replaced acute renal failure (ARF) as it more clearly defines renal dysfunction as a continuum rather than a discrete finding of failed kidney function. Pediatric AKI presents with a wide range of clinical manifestations from a minimal elevation in serum creatinine to anuric renal failure, arises from multiple causes and occurs in a variety of clinical settings [",
"    <a class=\"abstract\" href=\"UTD.htm?18/53/19290/abstract/1-7\">",
"     1-7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An overview of the causes, clinical presentation, and diagnosis of AKI in children will be presented here. The prevention and management of AKI in children and the approach to AKI in newborns are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/16/42249?source=see_link\">",
"     \"Prevention and management of acute kidney injury (acute renal failure) in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/30/27114?source=see_link\">",
"     \"Acute kidney injury (acute renal failure) in the newborn\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H694161131\">",
"    <span class=\"h1\">",
"     DEFINITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute kidney injury (AKI) is defined as a decrease in glomerular filtration rate (GFR), which traditionally is manifested by an elevated or a rise in serum creatinine. However, serum creatinine is often a delayed and imprecise test as it reflects GFR in individuals at steady state with stable kidney function, and does not accurately estimate the GFR in a patient whose renal function is changing. For example, a child in the early stages of severe AKI with a markedly reduced GFR may have a relatively normal or slightly elevated creatinine, as there has not been sufficient time for creatinine accumulation. In addition, creatinine is removed by dialysis, and it is not possible to assess renal function using serum creatinine once dialysis is initiated. Despite these limitations, elevated or a rise in serum creatinine continues to be the most widely used laboratory finding to make the diagnosis of AKI in children. (See",
"    <a class=\"local\" href=\"#H1479442760\">",
"     'Diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The inability of serum creatinine to accurately reflect kidney function has been especially problematic for clinical research in pediatric AKI. This has resulted in the use of more than 35 definitions of AKI in clinical studies, ranging from small changes in serum creatinine to dialysis requirement. Because of the lack of a consensus definition, comparisons among studies are difficult, resulting in a wide range of quoted epidemiology, morbidity, and mortality rates in the AKI pediatric literature. Recognizing a need for a consensus definition of AKI to facilitate clinical research on prevention and treatment of AKI, a consensus definition called the RIFLE classification of AKI based on changes in serum creatinine and urine output was developed by nephrologists and intensive care physicians [",
"    <a class=\"abstract\" href=\"UTD.htm?18/53/19290/abstract/8\">",
"     8",
"    </a>",
"    ]. The RIFLE criteria consists of three graded levels of injury (Risk, Injury, and Failure) based upon either the magnitude of elevation in serum creatinine or urine output, and two outcome measures (Loss and End-stage renal disease). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/49/42773?source=see_link\">",
"     \"Definition of acute kidney injury (acute renal failure)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H694161441\">",
"    <span class=\"h2\">",
"     pRIFLE",
"    </span>",
"    &nbsp;&mdash;&nbsp;pRIFLE is a pediatric modification of the adult RIFLE classification and consists of three graded levels of injury (Risk, Injury, and Failure) based upon the magnitude of change in estimated GFR or urine output, and two outcome measures (Loss of kidney function and End-stage renal disease) (",
"    <a class=\"graphic graphic_table graphicRef68721 \" href=\"UTD.htm?16/10/16555\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/53/19290/abstract/9\">",
"     9",
"    </a>",
"    ]. Differences between the adult and pediatric classification include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In pRIFLE, estimated creatinine clearance is based on the original Schwartz formula (",
"      <a class=\"calc calc_professional\" href=\"UTD.htm?23/40/24193?source=see_link\">",
"       calculator 1",
"      </a>",
"      ) to quantitate the change in GFR rather than absolute changes in serum creatinine used in the adult version of RIFLE. This modification takes into account the expected normal changes in serum creatinine concentrations that accompany somatic growth. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/9/11418?source=see_link&amp;anchor=H26#H26\">",
"       \"Clinical presentation and evaluation of chronic kidney disease in children\", section on 'Serum creatinine and GFR'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Immediate placement of any child with an estimated creatinine clearance &lt;35",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m",
"      <sup>",
"       2",
"      </sup>",
"      into the &ldquo;pRIFLE-F&rdquo; category (ie, kidney failure class), instead of waiting for the serum creatinine concentration to reach 4",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      as proposed for the original &ldquo;RIFLE-F&rdquo; staging. As an example, in infants and toddlers, a serum creatinine as low as 1.0 may reflect an estimated creatinine clearance &lt;35",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m",
"      <sup>",
"       2",
"      </sup>",
"      indicating renal failure.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The use of pRIFLE has been strongly advocated as a research and clinical tool as many experts in the field believe that it will improve the understanding of the epidemiology and outcomes of pediatric AKI. Support of pRIFLE is based on several reports that demonstrated AKI defined by the pRIFLE criteria was an independent risk factor for mortality and morbidity [",
"    <a class=\"abstract\" href=\"UTD.htm?18/53/19290/abstract/10-14\">",
"     10-14",
"    </a>",
"    ]. However, several limitations of the pRIFLE, which also apply to the adult RIFLE criteria, should be borne in mind. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/49/42773?source=see_link&amp;anchor=H3#H3\">",
"     \"Definition of acute kidney injury (acute renal failure)\", section on 'Limitations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The &ldquo;Risk&rdquo;, &ldquo;Injury&rdquo;, and &ldquo;Failure&rdquo; criteria are defined by changes in either estimated creatinine clearance OR changes in urine output. There is no clear evidence to suggest that these two changes correspond to the same degree of AKI severity.",
"     </li>",
"     <li>",
"      The pRIFLE criteria still depend on changes in serum creatinine, which have major limitations in AKI due to the inability of serum creatinine to accurately reflect changing renal function, as discussed above.",
"     </li>",
"     <li>",
"      Estimation of changes in creatinine clearance is challenging in children who do not have a pre-illness &ldquo;baseline&rdquo; serum creatinine measurement [",
"      <a class=\"abstract\" href=\"UTD.htm?18/53/19290/abstract/11,15\">",
"       11,15",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As a result of these limitations, a new definition of AKI referred to as the Acute Kidney Injury Network (AKIN) criteria was developed based on modification of the RIFLE criteria (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/49/42773?source=see_link&amp;anchor=H4#H4\">",
"     \"Definition of acute kidney injury (acute renal failure)\", section on 'AKIN criteria'",
"    </a>",
"    ). However, the AKIN criteria have not been adequately validated for use in children.",
"   </p>",
"   <p>",
"    Clinically, as discussed below, the most widely used laboratory finding to make the diagnosis of AKI remains an elevated (or a rise in) serum creatinine. (See",
"    <a class=\"local\" href=\"#H1479442760\">",
"     'Diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17720212\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The precise incidence and prevalence of pediatric acute kidney injury (AKI) are not known, largely due to the lack of a consensus definition in published studies. The incidence varies based on the definition used and potentially geographic location as demonstrated by the following [",
"    <a class=\"abstract\" href=\"UTD.htm?18/53/19290/abstract/11\">",
"     11",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A retrospective review from a regional tertiary center in England identified 227 children needing dialysis during an eight-year period, for an estimated yearly incidence of AKI defined by dialysis requirement of 0.8 per 100,000 population [",
"      <a class=\"abstract\" href=\"UTD.htm?18/53/19290/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another retrospective study from a tertiary care center in Thailand spanning 22 years reported a rise in the incidence of AKI (defined as a doubling of serum creatinine) with rates increasing from 4.6 to 9.9 cases per 1000 pediatric admissions in recent years [",
"      <a class=\"abstract\" href=\"UTD.htm?18/53/19290/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The underlying etiology of pediatric AKI also varies globally depending on the level of pediatric care:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In developed countries, the etiology of pediatric AKI has shifted during the past two decades from primary glomerular diseases to hospital-acquired causes of renal disease, especially in children with pre-existing chronic diseases. As a result, AKI may be multifactorial in etiology due to the underlying comorbid condition or its treatment, and may often involve multi-organ failure [",
"      <a class=\"abstract\" href=\"UTD.htm?18/53/19290/abstract/18\">",
"       18",
"      </a>",
"      ]. In tertiary centers in the United States, the most prevalent causes of AKI in critically ill children include sepsis, nephrotoxins, congenital heart disease, and renal ischemia [",
"      <a class=\"abstract\" href=\"UTD.htm?18/53/19290/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In less developed countries, acute tubular necrosis secondary to gastroenteritis with dehydration or sepsis, and primary renal diseases such as hemolytic uremic syndrome and acute glomerulonephritis are more likely to cause AKI [",
"      <a class=\"abstract\" href=\"UTD.htm?18/53/19290/abstract/17,19\">",
"       17,19",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H143536415\">",
"    <span class=\"h2\">",
"     Co-morbid conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;The overall incidence of AKI is rising in developed countries with the increasing use of intensive and advanced technology for children with chronic conditions or those who are critically ill [",
"    <a class=\"abstract\" href=\"UTD.htm?18/53/19290/abstract/5\">",
"     5",
"    </a>",
"    ]. As a result, the incidence of AKI is substantially higher in specialized populations with severe illnesses as illustrated by the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      AKI defined by a serum creatinine level of &gt;1.5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      is present in more than 30 percent of all preterm infants [",
"      <a class=\"abstract\" href=\"UTD.htm?18/53/19290/abstract/20\">",
"       20",
"      </a>",
"      ] and in about 50 percent of neonates with asphyxia [",
"      <a class=\"abstract\" href=\"UTD.htm?18/53/19290/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In children undergoing cardiac surgery for congenital heart diseases, the reported incidence of AKI from several studies utilizing the pRIFLE criteria is between 30 to 40 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?18/53/19290/abstract/22-27\">",
"       22-27",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In children receiving bone marrow transplants, the incidence of AKI (based on a doubling of serum creatinine) ranges from 15 to 34 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?18/53/19290/abstract/28,29\">",
"       28,29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In children admitted to pediatric intensive care units (PICU), the incidence of AKI defined by doubling of serum creatinine is about 5 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?18/53/19290/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a study using pRIFLE criteria, 6 percent of children had AKI on admission, and 10 percent developed AKI during their PICU stay [",
"      <a class=\"abstract\" href=\"UTD.htm?18/53/19290/abstract/12\">",
"       12",
"      </a>",
"      ]. In another PICU study that only included children receiving mechanical ventilation and vasopressors, the incidence of AKI jumped to 82 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?18/53/19290/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17605561\">",
"    <span class=\"h1\">",
"     CLASSIFICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several acute kidney injury (AKI) classification schemas have been developed.",
"   </p>",
"   <p>",
"    The most widely used classification and the one used in this review separates the causes of AKI into the following three categories based on the anatomic location of the initial injury. This schema is helpful for understanding the underlying pathophysiology and outlining a management approach. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/60/35785?source=see_link&amp;anchor=H2#H2\">",
"     \"Diagnostic approach to the patient with acute kidney injury (acute renal failure) or chronic kidney disease\", section on 'Major causes of kidney disease'",
"    </a>",
"    .).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Prerenal disease &ndash; Prerenal disease, also referred to as volume-responsive AKI",
"      <em>",
"       ,",
"      </em>",
"      is caused by reduced renal perfusion. It is the most common form of pediatric AKI and is due to hypovolemia (bleeding or gastrointestinal, urinary or cutaneous losses), or reduction of effective circulation (eg, heart failure, septic shock, and cirrhosis). In this form of AKI, although glomerular filtration rate (GFR) is reduced, renal tubular function remains intact with avid reabsorption of sodium and water in response to renal hypoperfusion, leading to oliguria. When normal renal perfusion is restored, urine flow and GFR usually return to normal.",
"     </li>",
"     <li>",
"      Intrinsic renal disease &ndash; Intrinsic or intrarenal AKI is characterized by structural damage to the renal parenchyma. The most common causes of intrinsic disease are prolonged hypoperfusion, sepsis, nephrotoxins, or severe glomerular diseases.",
"     </li>",
"     <li>",
"      Postrenal disease &ndash; Postrenal or obstructive AKI is typically the result of congenital or acquired anatomic obstructions to the lower urinary tract.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although less frequently used, AKI may also be classified by:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Clinical setting or circumstance",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Community-acquired",
"      <em>",
"      </em>",
"      AKI is more likely to be associated with a single predominant insult, most commonly volume depletion, and is frequently reversible. The management approach is often conservative and expectant. It includes correcting the initial insult, providing supportive fluid and electrolyte therapy, and awaiting spontaneous recovery of renal function.",
"     </li>",
"     <li>",
"      Hospital-acquired AKI, especially in the critical care setting, is frequently multifactorial and often part of a more extensive multi-organ failure. This form of AKI often accompanies other organ disease processes and markedly complicates patient management and outcome. Intervention is generally more aggressive with early initiation of renal replacement therapies to optimize the overall care of the severely compromised patient. Recovery is partial at best, and there are usually significant short- and long-term consequences.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Urine output &ndash; Measurement of urine output is especially useful in the critical care setting, since the degree of oliguria affects fluid and electrolyte management. However, the presence of a normal volume of urine does not preclude AKI.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Anuria, no urine output",
"     </li>",
"     <li>",
"      Oliguria defined as urine output &lt;1",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      per hour in infants, and in children and adults, urine output &lt;0.5",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      per hour for greater than six hours",
"     </li>",
"     <li>",
"      Nonoliguria &ndash; The majority of neonates with AKI will have nonoliguric AKI, even those with moderate to severe impairment of kidney function",
"     </li>",
"     <li>",
"      Polyuria &ndash; Some patients with a urinary concentrating defect will present with polyuric AKI, particularly those with acute tubular necrosis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17605650\">",
"    <span class=\"h1\">",
"     ETIOLOGY AND PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;As discussed above, the causes and mechanisms of pediatric acute kidney injury (AKI) can be classified based on the anatomic location of the initial injury.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Vascular &ndash; Blood from the renal arteries is delivered to the glomeruli. Interruption of perfusion to the kidneys results in prerenal AKI.",
"     </li>",
"     <li>",
"      Glomeruli &ndash; Ultrafiltration occurs at the glomeruli forming an ultrafiltrate, which subsequently flows into the renal tubules. Glomerular injury resulting in disruption of glomerular filtration rate (GFR) is one of the major causes of intrinsic AKI.",
"     </li>",
"     <li>",
"      Renal tubule &ndash; Reabsorption and secretion of solute",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      water from the ultrafiltrate occurs within the tubules. Acute tubular necrosis due to nephrotoxins or hypoperfusion is one of the major causes of intrinsic AKI.",
"     </li>",
"     <li>",
"      Urinary tract &ndash; The final tubular fluid, the urine, leaves the kidney, draining sequentially into the renal pelvis, ureter, and bladder, and from which it is excreted through the urethra. Postrenal AKI is due to obstruction of urine anywhere along the urinary tract in a single kidney, and in patients with two kidneys, bilateral obstruction usually at the bladder or urethral level.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17605643\">",
"    <span class=\"h2\">",
"     Prerenal AKI",
"    </span>",
"    &nbsp;&mdash;&nbsp;Causes of prerenal AKI (",
"    <a class=\"graphic graphic_table graphicRef50307 \" href=\"UTD.htm?4/1/4123\">",
"     table 2",
"    </a>",
"    ) result in decreased perfusion to the kidneys, and as a consequence a reduction in GFR due to the following two pathogenetic mechanisms:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      True volume depletion due to bleeding (eg, surgery or trauma), intestinal loss (eg, gastroenteritis), or excessive cutaneous loss (eg, burns).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Effective renal hypoperfusion as a result of decreased arterial pressure (due to decreased cardiac output [heart failure]) or effective arterial blood volume (due to decreased intravascular volume despite normal or increased total body water [eg, septic shock or cirrhosis]). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/48/11018?source=see_link&amp;anchor=H96014906#H96014906\">",
"       \"General principles of disorders of water balance (hyponatremia and hypernatremia) and sodium balance (hypovolemia and edema)\", section on 'Regulation of effective arterial blood volume'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In patients with decreased arterial blood volume, the release of vasoactive agents (norepinephrine and angiotensin II) is one of the main systemic compensatory mechanisms that maintains perfusion to the brain and heart by normalizing intravascular volume and blood pressure, but diminishes renal perfusion and as a consequence reduces GFR.",
"   </p>",
"   <p>",
"    There are several renal compensatory mechanisms that attempt to maintain GFR in patients with decreased renal perfusion.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The most effective of these renal compensatory systems involves the increased intrarenal generation of vasodilatory prostaglandins. Non-steroidal anti-inflammatory drugs (NSAIDs), however, inhibit this response and can therefore precipitate AKI even when following appropriate dosing [",
"      <a class=\"abstract\" href=\"UTD.htm?18/53/19290/abstract/31\">",
"       31",
"      </a>",
"      ]. The risk of AKI is higher when these agents are used in the setting of renal hypoperfusion. Two common pediatric scenarios in which this occurs are the use of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/27/17848?source=see_link\">",
"       indomethacin",
"      </a>",
"      for closure of a patent ductus arteriosus in neonates, and the use of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/48/7946?source=see_link\">",
"       ibuprofen",
"      </a>",
"      in febrile children with hypovolemia due to gastroenteritis.",
"     </li>",
"     <li>",
"      A second mechanism involves intra-renal angiotensin II, which constricts both the afferent and efferent arteriole. The effect is greater in the efferent arteriole leading to increased hydrostatic pressure across the glomerulus and maintenance of GFR. The administration of angiotensin-converting enzyme (ACE) inhibitor therapy blocks this compensatory mechanism.",
"     </li>",
"     <li>",
"      Myogenic autoregulation refers to the unique ability of the afferent arterioles to vasodilate in response to a decrease in lateral stretch caused by hypoperfusion. Calcineurin inhibitors such as",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/24/34176?source=see_link\">",
"       cyclosporine",
"      </a>",
"      and",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/53/34640?source=see_link\">",
"       tacrolimus",
"      </a>",
"      that are commonly used for immunosuppression following kidney transplants can interfere with this myogenic response.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17605664\">",
"    <span class=\"h2\">",
"     Intrinsic AKI",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common underlying etiology for intrinsic AKI is prolonged renal hypoperfusion. However, in critical care settings, intrinsic AKI is frequently multifactorial in etiology with concurrent ischemic, nephrotoxic, and septic insults that can exacerbate the severity of renal injury.",
"   </p>",
"   <p>",
"    Intrinsic AKI can be classified further into disorders that affect the renal vasculature, glomeruli, tubule, and interstitium (",
"    <a class=\"graphic graphic_table graphicRef72891 \" href=\"UTD.htm?3/57/3995\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1479442591\">",
"    <span class=\"h3\">",
"     Vascular disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pediatric renal vascular causes of intrinsic AKI include thrombosis (arterial and venous), hemolytic uremic syndrome, and vasculitides. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/55/35704?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Shiga toxin associated (typical) hemolytic uremic syndrome in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/42/40616?source=see_link\">",
"     \"Classification and incidence of childhood vasculitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1479442637\">",
"    <span class=\"h3\">",
"     Glomerular disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The principal pediatric glomerular cause of AKI is acute glomerulonephritis, which is most commonly poststreptococcal, and an important etiology in developing countries. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/30/35304?source=see_link\">",
"     \"Poststreptococcal glomerulonephritis in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/1/12311?source=see_link\">",
"     \"Overview of the pathogenesis and causes of glomerulonephritis in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17605683\">",
"    <span class=\"h3\">",
"     Tubular and interstitial disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prolonged prerenal AKI with reduction in renal perfusion, and tubular nephrotoxins are important causes of intrinsic AKI. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/54/12138?source=see_link\">",
"     \"Etiology and diagnosis of prerenal disease and acute tubular necrosis in acute kidney injury (acute renal failure)\"",
"    </a>",
"    .).",
"   </p>",
"   <p>",
"    Common exogenous nephrotoxins include aminoglycosides,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/12/201?source=see_link\">",
"     amphotericin B",
"    </a>",
"    , contrast agents, calcineurin inhibitors, and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/8/34949?source=see_link\">",
"     cisplatin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?18/53/19290/abstract/13,32\">",
"     13,32",
"    </a>",
"    ] (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/47/20215?source=see_link\">",
"     \"Manifestations of and risk factors for aminoglycoside nephrotoxicity\"",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Acute interstitial nephritis from a reaction to several drugs can also cause acute intrinsic AKI. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/36/27209?source=see_link\">",
"     \"Clinical manifestations and diagnosis of acute interstitial nephritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Intrinsic AKI can also be induced by the release of endogenous nephrotoxins such as myoglobinuria due to rhabdomyolysis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/53/19290/abstract/33\">",
"     33",
"    </a>",
"    ] and hemoglobinuria due to intravascular hemolysis (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/6/22632?source=see_link\">",
"     \"Clinical features and diagnosis of heme pigment-induced acute kidney injury (acute renal failure)\"",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17605704\">",
"    <span class=\"h2\">",
"     Postrenal AKI",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postrenal AKI is due to bilateral urinary tract obstruction or obstruction of the urinary tract of a solitary kidney. Causes of postrenal AKI include renal calculi, clots, neurogenic bladder, and medications that cause urinary retention. Children with chronic kidney disease from uncorrected congenital obstructive uropathies remain at significant risk of AKI from ischemic, septic, and nephrotoxic insults. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/60/22472?source=see_link&amp;anchor=H13#H13\">",
"     \"Overview of congenital anomalies of the kidney and urinary tract (CAKUT)\", section on 'Anomalies of the collecting system'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/0/11271?source=see_link\">",
"     \"Clinical presentation and diagnosis of posterior urethral valves\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17605795\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute kidney injury (AKI) in children can present in several different ways.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In most children, AKI presents with signs and symptoms that result directly from alterations of renal function. These include edema (due to progressive fluid accumulation), decreased or no urine output, gross and microscopic hematuria,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      hypertension. In these patients, there is often a known etiologic factor that predisposes the child to AKI, such as shock or heart failure, or a preceding streptococcal infection seen in patients with poststreptococcal glomerulonephritis. (See",
"      <a class=\"local\" href=\"#H33652950\">",
"       'History'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Laboratory monitoring of at-risk patients identifies alterations of renal function, such as elevations of serum creatinine",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      blood urea nitrogen (BUN) or abnormal urinalysis. For example, ongoing monitoring frequently will identify a rise in serum creatinine in children post-cardiac surgery or preterm infants with a patent ductus arteriosus treated with",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/27/17848?source=see_link\">",
"       indomethacin",
"      </a>",
"      .",
"      <br/>",
"      <br/>",
"      AKI, identified by laboratory testing, is common in critically ill patients with multi-organ failure or dysfunction [",
"      <a class=\"abstract\" href=\"UTD.htm?18/53/19290/abstract/9,12,32\">",
"       9,12,32",
"      </a>",
"      ]. In these patients cared for in the intensive care setting, prognosis is guarded as AKI is associated with a mortality rate of more than 50 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?18/53/19290/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Less frequently, patients without signs or symptoms of renal injury will present as a result of unexpected laboratory findings of an elevated serum creatinine or BUN, or abnormal urinalysis. This may occur in a patient presenting with vasculitis (eg, Henoch-Sch&ouml;nlein purpura) who initially presents with a rash, arthritis, and abdominal pain, in whom the initial evaluation demonstrates an elevated serum creatinine",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      abnormal urinalysis. In addition, patients with acute interstitial nephritis may also present with an acute rise in serum creatinine and an abnormal urinalysis with no or nonspecific symptoms (eg, malaise and vomiting). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/49/40729?source=see_link&amp;anchor=H4#H4\">",
"       \"Clinical manifestations and diagnosis of Henoch-Sch&ouml;nlein purpura (IgA vasculitis)\", section on 'Clinical manifestations in children'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/36/27209?source=see_link&amp;anchor=H6#H6\">",
"       \"Clinical manifestations and diagnosis of acute interstitial nephritis\", section on 'Clinical features'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20044887\">",
"    <span class=\"h2\">",
"     Other laboratory findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to an elevated serum creatinine or BUN, disruption of renal function may result in the following abnormal laboratory findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hyperkalemia &ndash; Several factors may contribute to hyperkalemia in patients with AKI. These include a reduced glomerular filtration rate (GFR), decreased tubular secretion of potassium, tissue breakdown with release of intracellular potassium, and metabolic acidosis resulting in transcellular movement of potassium (each 0.1 unit reduction in arterial pH raises serum potassium by 0.3",
"      <span class=\"nowrap\">",
"       mEq/L).",
"      </span>",
"      Hyperkalemia is most pronounced in patients with significant tissue breakdown (rhabdomyolysis, hemolysis, and tumor lysis syndrome). Symptoms are non-specific and may include malaise, nausea, and muscle weakness. Electrocardiogram (ECG) changes occur in patients with hyperkalemia. These include (in sequence according to the severity of hyperkalemia) tall peaked T waves, prolonged PR interval, flattened P waves, widened QRS complex, ventricular tachycardia, and fibrillation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/5/33882?source=see_link\">",
"       \"Causes and evaluation of hyperkalemia in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/2/44069?source=see_link\">",
"       \"Clinical manifestations of hyperkalemia in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Abnormal serum sodium",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Hyponatremia is a common laboratory finding and generally due to dilution from fluid retention",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      administration of hypotonic fluids. Less common causes of hyponatremia include sodium depletion (hyponatremic dehydration), hyperglycemia (serum sodium concentration decreases by 1.6",
"      <span class=\"nowrap\">",
"       mEq/L",
"      </span>",
"      for every 100",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      increase in serum glucose above 100",
"      <span class=\"nowrap\">",
"       mg/dL),",
"      </span>",
"      and pseudohyponatremia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/30/3562?source=see_link\">",
"       \"Causes of hyponatremia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hypernatremia is less common in children with AKI. It is usually due to hypernatremic dehydration causing pre-renal failure, excessive sodium administration (eg, excessive",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/56/41862?source=see_link\">",
"       sodium bicarbonate",
"      </a>",
"      administration),",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      the inability to excrete a sodium load. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/63/36857?source=see_link&amp;anchor=H141685781#H141685781\">",
"       \"Etiology and evaluation of hypernatremia\", section on 'Etiology of hypernatremia'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A high anion gap metabolic acidosis is common, and is secondary to the impaired renal excretion of acid, and reabsorption and regeneration of bicarbonate. Acidosis is most severe in critically ill children with shock, sepsis, or impaired respiratory compensation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/11/6330?source=see_link&amp;anchor=H12#H12\">",
"       \"Approach to the child with metabolic acidosis\", section on 'Elevated AG acidosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hypocalcemia is commonly encountered in AKI, and is due to increased serum phosphate and impaired renal conversion of vitamin D to the active form. Hypocalcemia is most pronounced in patients with rhabdomyolysis. Metabolic acidosis increases the fraction of ionized calcium (the active form). Therefore, it is important that the clinician is aware that rapid correction with bicarbonate therapy can decrease the concentration of ionized calcium and precipitate symptoms of hypocalcemia (eg, tetany, seizures, and cardiac arrhythmias).",
"     </li>",
"     <li>",
"      Hyperphosphatemia in AKI is primarily due to impaired renal excretion and can contribute to hypocalcemia. Hyperphosphatemia is most pronounced in patients with significant tissue breakdown (eg, tumor lysis syndrome or rhabdomyolysis).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1479442760\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of acute kidney injury (AKI) is made clinically based on the presence of characteristic signs and symptoms, and laboratory findings indicative of an acute change in renal function.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Signs and symptoms include edema, decreased or no urine output, gross hematuria",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      hypertension. (See",
"      <a class=\"local\" href=\"#H17605795\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Laboratory findings include elevated or rising serum creatinine. An abnormal urinalysis may also provide support for acute injury to the kidney.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The above findings typically occur in a clinical setting, in which AKI is an expected or reasonable consequence (eg, critically ill patient or a condition, in which renal disease is often encountered). Further evaluation is generally focused on identifying the underlying cause",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    contributing factors of AKI. (See",
"    <a class=\"local\" href=\"#H17605854\">",
"     'Identifying the underlying cause'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1562454639\">",
"    <span class=\"h2\">",
"     Laboratory tests",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1562454647\">",
"    <span class=\"h3\">",
"     Serum creatinine",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common laboratory test used to identify reduced glomerular filtration rate (GFR) as an indication of AKI is serum creatinine. As noted above, serum creatinine only accurately reflects GFR in patients with stable kidney function; however, in most clinical settings of AKI, the exact knowledge of GFR is not required. What is clinically important is whether there is a reduction of GFR due to renal injury, which is reflected by an increase in serum creatinine.",
"   </p>",
"   <p>",
"    As a result, in most settings, an elevated creatinine is used to make the diagnosis of AKI. However, an initial creatinine level may not be helpful as baseline creatinine levels are unknown in the majority of children, and normal serum creatinine levels vary depending on the age, gender, muscle mass, and the nutritional and hydration status of the child.",
"   </p>",
"   <p>",
"    The following are the ranges of normal serum creatinine values by age [",
"    <a class=\"abstract\" href=\"UTD.htm?18/53/19290/abstract/35\">",
"     35",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Newborn &ndash; 0.3 to 1.0",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (27 to 88",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"     </li>",
"     <li>",
"      Infant &ndash; 0.2 to 0.4",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (18 to 35",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"     </li>",
"     <li>",
"      Child &ndash; 0.3 to 0.7",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (27 to 62",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"     </li>",
"     <li>",
"      Adolescent &ndash; 0.5 to 1.0",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (44 to 88",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Because of the wide range of normal serum creatinine, an initial value of 0.4",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (35",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    may be normal or elevated in an infant or young child. In a child whose normal creatinine is 0.2",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (18 micromol), a serum creatinine of 0.4",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (35",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    may reflect a 50 percent or greater decrease in GFR.",
"   </p>",
"   <p>",
"    When it is uncertain whether the GFR is reduced based on an initial creatinine, subsequent measurements showing a daily rise in serum creatinine or at 12-hour intervals confirms the diagnosis of AKI. The change in creatinine is dependent on the amount of residual renal function, the endogenous production of creatinine based on muscle mass, and the volume of distribution. In some settings, the serum creatinine may not rise until there is a 50 percent or more reduction in GFR.",
"   </p>",
"   <p>",
"    Despite these limitations, there is currently no better laboratory test to make the diagnosis of AKI in children.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1562454701\">",
"    <span class=\"h2\">",
"     Urinalysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;An abnormal urinalysis provides supportive diagnostic evidence for AKI. However, in patients with prerenal AKI, the urinalysis may be normal. In contrast, patients with intrinsic AKI, particularly those with glomerular disease or acute tubular necrosis, commonly will have hematuria",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    proteinuria. Thus, a normal urinalysis does not preclude the diagnosis of AKI.",
"   </p>",
"   <p>",
"    Urinalysis is often helpful in identifying the underlying cause of AKI as discussed below. (See",
"    <a class=\"local\" href=\"#H33653144\">",
"     'Urinalysis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1562454743\">",
"    <span class=\"h2\">",
"     Biomarkers of AKI",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because serum creatinine is often a delayed and imprecise test for AKI, research has focused on identifying biomarkers that accurately predict AKI in the early stages of injury. Novel biomarkers, such as neutrophil gelatinase-associated lipocalin (NGAL), kidney injury molecule-1 (KIM-1), and interleukin-18 (IL-18) show promise in both their diagnostic and prognostic utility in the setting of AKI, and may allow for early intervention prior to the onset of SCr rise, severe metabolic derangements, and fluid overload [",
"    <a class=\"abstract\" href=\"UTD.htm?18/53/19290/abstract/3,7,36-39\">",
"     3,7,36-39",
"    </a>",
"    ]. However, future studies are needed to establish whether any of these markers will provide beneficial clinical guidance in the diagnosis and management of AKI in children. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/1/34839?source=see_link&amp;anchor=H22961934#H22961934\">",
"     \"Investigational biomarkers and the evaluation of acute tubular necrosis\", section on 'Overview'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33650600\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common differential diagnosis for acute kidney injury (AKI) is the initial presentation of chronic kidney disease. The distinction between these two forms of renal disease is based on disease duration. The disease process in patients with AKI generally resolves over days and weeks, whereas, those with CKD will have persistent renal dysfunction for months to years. As an example, children with AKI due to acute poststreptococcal glomerulonephritis (PSGN) and those with CKD due to membranoproliferative glomerulonephritis (MPGN) may both present acutely with edema, hematuria, hypertension, and hypocomplementemia. In patients with PSGN, symptoms generally resolve and the C3 level returns to normal by four to six weeks. In contrast, those with MPGN continue to have persistent signs of nephritis and hypocomplementemia beyond two months. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/30/35304?source=see_link&amp;anchor=H17#H17\">",
"     \"Poststreptococcal glomerulonephritis in children\", section on 'Differential diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although the initial presentation may be similar with signs and symptoms of impaired renal function, a number of findings may differentiate the two different types of renal disease (",
"    <a class=\"graphic graphic_table graphicRef82873 \" href=\"UTD.htm?28/29/29147\">",
"     table 4",
"    </a>",
"    ). For example, children with CKD may have impaired growth or a history of chronic hypertension. In addition, renal ultrasound may be helpful as kidneys in patients with CKD are frequently small due to nephron loss or congenital hypoplasia, whereas the kidneys in patients with AKI are normal in size or enlarged (due to inflammation or edema). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/9/11418?source=see_link&amp;anchor=H24#H24\">",
"     \"Clinical presentation and evaluation of chronic kidney disease in children\", section on 'Imaging'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17605854\">",
"    <span class=\"h1\">",
"     IDENTIFYING THE UNDERLYING CAUSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once the diagnosis of known or suspected acute kidney injury (AKI) is made, further evaluation is focused towards identifying the underlying cause. &nbsp;",
"   </p>",
"   <p>",
"    The evaluation consists of a complete history, physical examination, and laboratory evaluation. Renal imaging is often performed and rarely, a kidney biopsy is required.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33652950\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial history is directed towards uncovering an obvious risk factor or cause for AKI (",
"    <a class=\"graphic graphic_table graphicRef50307 \" href=\"UTD.htm?4/1/4123\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef72891 \" href=\"UTD.htm?3/57/3995\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The following historical findings are often indicative of an underlying etiology (",
"    <a class=\"graphic graphic_table graphicRef82870 \" href=\"UTD.htm?22/22/22891\">",
"     table 5",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A short duration of vomiting, diarrhea, or decreased oral intake associated with decreased urine output suggests prerenal AKI.",
"     </li>",
"     <li>",
"      A history of bloody diarrhea, three to seven days prior to the onset of oliguria suggests hemolytic uremic syndrome. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/55/35704?source=see_link\">",
"       \"Clinical manifestations and diagnosis of Shiga toxin associated (typical) hemolytic uremic syndrome in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A history of pharyngitis or impetigo a few weeks prior to the onset of gross hematuria or edema suggests poststreptococcal glomerulonephritis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/30/35304?source=see_link\">",
"       \"Poststreptococcal glomerulonephritis in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In hospitalized patients, nephrotoxic medications or periods of hypotension are associated with intrinsic AKI.",
"     </li>",
"     <li>",
"      Other systemic complaints (eg, fever, joint complaints, and rash) may be seen in patients with autoimmune disease or vasculitide, such as Henoch-Sch&ouml;nlein purpura. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/49/40729?source=see_link\">",
"       \"Clinical manifestations and diagnosis of Henoch-Sch&ouml;nlein purpura (IgA vasculitis)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A diligent search for all drugs and medications ingested is especially important, even when another obvious cause for AKI is evident.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33653023\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The physical examination should include measurement of blood pressure, and assessment for edema and recent weight gain, and signs of systemic disease, such as rash or joint disease.",
"   </p>",
"   <p>",
"    The presence of the following physical findings often points to a specific underlying etiology (",
"    <a class=\"graphic graphic_table graphicRef82871 \" href=\"UTD.htm?40/26/41387\">",
"     table 6",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Signs of volume depletion (eg, dry mucous membranes, tachycardia, decreased skin turgor, orthostatic falls in blood pressure, and decreased peripheral perfusion) are indicative of prerenal AKI.",
"     </li>",
"     <li>",
"      Edema may be present in children with nephrotic syndrome or glomerulonephritis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/39/1657?source=see_link&amp;anchor=H8#H8\">",
"       \"Pathophysiology and etiology of edema in children\", section on 'Etiology'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hypertension is a common finding in children with glomerulonephritis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/7/42105?source=see_link&amp;anchor=H16#H16\">",
"       \"Epidemiology, risk factors, and etiology of hypertension in children and adolescents\", section on 'Renal parenchymal disease'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/62/11238?source=see_link&amp;anchor=H4#H4\">",
"       \"Evaluation of a child with glomerular disease\", section on 'Clinical features'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Rash is commonly seen in children with AKI due to Henoch-Sch&ouml;nlein purpura, interstitial nephritis, and the acute onset of systemic lupus erythematosus. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/35/10810?source=see_link&amp;anchor=H5#H5\">",
"       \"Systemic lupus erythematosus in children\", section on 'Renal disease'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/49/40729?source=see_link&amp;anchor=H4#H4\">",
"       \"Clinical manifestations and diagnosis of Henoch-Sch&ouml;nlein purpura (IgA vasculitis)\", section on 'Clinical manifestations in children'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/54/5993?source=see_link\">",
"       \"Renal manifestations of Henoch-Sch&ouml;nlein purpura\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Enlarged palpable kidneys may be an indication of renal vein thrombosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/28/25033?source=see_link&amp;anchor=H12#H12\">",
"       \"Pathogenesis and clinical manifestations of venous thrombosis and thromboembolism in infants and children\", section on 'Renal vein thrombosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      An enlarged bladder may suggest urethral obstruction.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33653118\">",
"    <span class=\"h2\">",
"     Laboratory and imaging evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laboratory tests and renal imaging that may be useful in determining the underlying etiology of AKI include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Urinalysis",
"     </li>",
"     <li>",
"      Fractional sodium excretion to differentiate between pre- and intrinsic AKI",
"     </li>",
"     <li>",
"      Renal ultrasound",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33653144\">",
"    <span class=\"h3\">",
"     Urinalysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The urinalysis is often helpful in determining the underlying cause of AKI, as characteristic findings are suggestive of certain disease processes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/34/22058?source=see_link\">",
"     \"Urinalysis in the diagnosis of kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Muddy brown granular casts and epithelial cell casts are highly suggestive of intrinsic AKI or acute tubular necrosis (ATN) (",
"      <a class=\"graphic graphic_picture graphicRef56438 graphicRef65729 graphicRef78655 \" href=\"UTD.htm?18/40/19080\">",
"       picture 1A-C",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/34/22058?source=see_link\">",
"       \"Urinalysis in the diagnosis of kidney disease\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/54/12138?source=see_link\">",
"       \"Etiology and diagnosis of prerenal disease and acute tubular necrosis in acute kidney injury (acute renal failure)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The finding of red cell casts is diagnostic of glomerulonephritis. The concurrent finding of dysmorphic red cells and heavy proteinuria indicates an active &ldquo;nephritic&rdquo; urinary sediment, which is also commonly associated with glomerulonephritis (",
"      <a class=\"graphic graphic_picture graphicRef55778 \" href=\"UTD.htm?34/38/35424\">",
"       picture 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef79440 \" href=\"UTD.htm?24/0/24591\">",
"       picture 3",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef62064 \" href=\"UTD.htm?13/47/14079\">",
"       picture 4",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/62/11238?source=see_link&amp;anchor=H5#H5\">",
"       \"Evaluation of a child with glomerular disease\", section on 'Urinalysis and urinary protein'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pyuria with white cell, granular or waxy casts are suggestive of tubular or interstitial disease, or urinary tract infection (",
"      <a class=\"graphic graphic_picture graphicRef75211 graphicRef54319 graphicRef68147 graphicRef59811 graphicRef65483 \" href=\"UTD.htm?30/59/31674\">",
"       picture 5A-E",
"      </a>",
"      ). White cells and white cell casts may also be seen in acute glomerulonephritis.",
"     </li>",
"     <li>",
"      A positive response for heme on a urine dipstick in the absence of red blood cells in the sediment is seen in patients with hemolysis or rhabdomyolysis.",
"     </li>",
"     <li>",
"      The urinalysis in children with prerenal AKI is typically normal.",
"     </li>",
"     <li>",
"      Urine specific gravity &ndash; Loss of concentrating ability is an early and almost universal finding in ATN with a urine specific gravity below 1.010. In contrast, urine specific gravity greater than 1.020 is suggestive of prerenal disease.",
"      <br/>",
"      <br/>",
"      Urine osmolality is a more accurate measure of concentrating ability. Patients with ATN generally have urine osmolality below 350",
"      <span class=\"nowrap\">",
"       mosmol/kg,",
"      </span>",
"      whereas patients with prerenal disease usually have values above 500",
"      <span class=\"nowrap\">",
"       mosmol/kg.",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20042727\">",
"    <span class=\"h3\">",
"     Tests to distinguish between prerenal and intrinsic ATN",
"    </span>",
"   </p>",
"   <p>",
"    (",
"    <a class=\"graphic graphic_table graphicRef82872 \" href=\"UTD.htm?11/0/11275\">",
"     table 7",
"    </a>",
"    )",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17605911\">",
"    <span class=\"h4\">",
"     Fractional excretion of sodium",
"    </span>",
"    &nbsp;&mdash;&nbsp;The fractional excretion of sodium (FENa) is the most commonly used laboratory test to differentiate between prerenal AKI and intrinsic disease due to ATN. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/17/8472?source=see_link\">",
"     \"Fractional excretion of sodium, urea, and other molecules in acute kidney injury (acute renal failure)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    FENa is calculated from measured concentrations of urinary sodium (UNa) and creatinine (UCr), and plasma sodium (PNa) and creatinine (PCr):",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; UNa &nbsp; x &nbsp; SCr",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;FENa, percent &nbsp; &nbsp;= &nbsp; &nbsp; &nbsp; &mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash; &nbsp; &nbsp;x &nbsp; &nbsp;100",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; SNa &nbsp; x &nbsp; UCr",
"   </p>",
"   <p>",
"    Calculators are available for FENa expressed using either standard units (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?25/13/25809?source=see_link\">",
"     calculator 2",
"    </a>",
"    ) or SI (international units) (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?24/28/25025?source=see_link\">",
"     calculator 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    FENa is a direct measurement of the renal handling of sodium, which is similar in children and adults. As a result, the FENa values in children that differentiate prerenal AKI from ATN are the same as those used in adults.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A FENa below 1 percent suggests prerenal AKI, in which the reabsorption of almost all the filtered sodium represents an appropriate response to decreased perfusion",
"     </li>",
"     <li>",
"      A FENa above 2 percent suggests ATN",
"     </li>",
"     <li>",
"      A FENa between 1 and 2 percent is non-diagnostic",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, in neonates, especially preterm infants, sodium reabsorption is decreased. As a result, the FENa cutoff values differentiating prerenal AKI and ATN in neonates are higher. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/30/27114?source=see_link&amp;anchor=H20#H20\">",
"     \"Acute kidney injury (acute renal failure) in the newborn\", section on 'FENa'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In term infants, the FENa is usually below 2 percent in prerenal AKI and usually greater than 2.5 percent in ATN.",
"     </li>",
"     <li>",
"      In preterm infants, FENa cutoff values increase with decreasing gestational age, although it is unclear how helpful FENa is in differentiating between prerenal disease and ATN.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Limitations in use of FENa include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Previous fluid administration",
"     </li>",
"     <li>",
"      Diuretic therapy",
"     </li>",
"     <li>",
"      AKI due to contrast nephropathy or pigment nephropathy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33653840\">",
"    <span class=\"h4\">",
"     Other tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other tests that have been used to distinguish between prerenal disease and ATN include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Serum",
"      <span class=\"nowrap\">",
"       BUN/creatinine",
"      </span>",
"      ratio is markedly elevated (&gt;20) in patients with prerenal AKI, whereas, in patients with ATN, it remains in the normal range of 10 to 15. The difference is due to the avid urea reabsorption by the proximal tubule, which is impermeable to creatinine. However, the utility of this test is limited because elevated BUN is seen in patients with increased urea production due to administration of steroids or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/40/42628?source=see_link\">",
"       total parenteral nutrition",
"      </a>",
"      , tissue breakdown (catabolism), or gastrointestinal bleeding.",
"     </li>",
"     <li>",
"      The fractional excretion of urea (FEUrea) has been proposed as a more accurate determinant of prerenal AKI, especially in patients receiving diuretics [",
"      <a class=\"abstract\" href=\"UTD.htm?18/53/19290/abstract/40\">",
"       40",
"      </a>",
"      ]. Patients with prerenal AKI generally have FEUrea below 35 percent, while patients with ATN will have FEUrea &gt;50 percent. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/17/8472?source=see_link&amp;anchor=H7#H7\">",
"       \"Fractional excretion of sodium, urea, and other molecules in acute kidney injury (acute renal failure)\", section on 'Fractional excretion of other molecules'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20043896\">",
"    <span class=\"h4\">",
"     Diagnostic fluid challenge",
"    </span>",
"    &nbsp;&mdash;&nbsp;In some cases, a fluid challenge of 10 to 20",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    of normal saline may be diagnostic as well as therapeutic. This intervention may be useful in the following two clinical scenarios:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients present with an increase in serum creatinine and a history and physical findings consistent with a prerenal etiology, but the duration of the prerenal insult is unknown.",
"     </li>",
"     <li>",
"      Patients present with an increase in serum creatinine but the cause is unclear.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    After administration of a fluid bolus, a reduction in BUN and serum creatinine would indicate a prerenal etiology, whereas an absence of improvement in these parameters",
"    <span class=\"nowrap\">",
"     (and/or",
"    </span>",
"    the development of fluid overload) would suggest a diagnosis of intrinsic AKI.",
"   </p>",
"   <p>",
"    Fluid challenge is",
"    <strong>",
"     contraindicated",
"    </strong>",
"    in patients with obvious volume overload or heart failure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20044988\">",
"    <span class=\"h2\">",
"     Additional laboratory measurements",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other laboratory studies that may be useful in determining the underlying etiology of AKI include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Complete blood count &ndash; Microangiopathic hemolytic anemia associated with thrombocytopenia in the setting of AKI is diagnostic for hemolytic uremic syndrome. Severe hemolysis, whether drug-induced or secondary to hemoglobinopathies, may also result in ATN due to massive hemoglobinuria. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/55/35704?source=see_link\">",
"       \"Clinical manifestations and diagnosis of Shiga toxin associated (typical) hemolytic uremic syndrome in children\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Eosinophilia",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      urine eosinophiluria may be present in some cases of interstitial nephritis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/36/27209?source=see_link\">",
"       \"Clinical manifestations and diagnosis of acute interstitial nephritis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Complement studies including C3, C4, CH50 and AH50 &ndash; Hypocomplementemia is seen in patients with poststreptococcal glomerulonephritis (PSGN), shunt nephritis, and nephritis associated with subacute bacterial endocarditis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/62/11238?source=see_link&amp;anchor=H9#H9\">",
"       \"Evaluation of a child with glomerular disease\", section on 'Blood tests'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/25/10647?source=see_link\">",
"       \"Overview and clinical assessment of the complement system\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Serologic testing for streptococcal infection &ndash; The presence of antistreptococcal antibodies is a diagnostic criterion for PSGN. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/30/35304?source=see_link&amp;anchor=H14#H14\">",
"       \"Poststreptococcal glomerulonephritis in children\", section on 'Serology'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Elevated serum levels of aminoglycosides are associated with ATN. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/41/18072?source=see_link\">",
"       \"Pathogenesis and prevention of aminoglycoside nephrotoxicity and ototoxicity\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Uric acid &ndash; AKI may result from markedly elevated uric acid levels, which may occur in children with tumor lysis syndrome secondary to chemotherapy treatment of childhood leukemia or lymphoma. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/1/19481?source=see_link\">",
"       \"Tumor lysis syndrome: Definition, pathogenesis, clinical manifestations, etiology and risk factors\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/57/27541?source=see_link\">",
"       \"Uric acid renal diseases\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1873188\">",
"    <span class=\"h2\">",
"     Renal imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;A renal ultrasound should be considered in all children with AKI of unclear etiology. It can document the presence of one or two kidneys, delineate renal size, and survey the renal parenchyma. It is also particularly helpful in diagnosing urinary tract obstruction or occlusion of the major renal vessels. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/37/39509?source=see_link\">",
"     \"Radiologic assessment of renal disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, renal ultrasound may be useful in differentiating AKI from chronic kidney disease (CKD). Typically, the kidneys in AKI are normal in size or enlarged (due to inflammation or edema), with increased echogenicity, whereas those in CKD are frequently small and shrunken. (See",
"    <a class=\"local\" href=\"#H33650600\">",
"     'Differential diagnosis'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20045402\">",
"    <span class=\"h2\">",
"     Renal biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A renal biopsy is rarely indicated in AKI but should be considered when noninvasive evaluation fails to establish a diagnosis. In pediatric AKI, it is most commonly indicated to help guide treatment in patients with suspected acute glomerulonephritis (to identify crescentic forms or specific vasculitides) or suspected lupus nephritis (to classify the disease and establish the activity and chronicity). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/11/21690?source=see_link\">",
"     \"Indications for and complications of renal biopsy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?5/46/5859?source=see_link\">",
"       \"Patient information: Acute kidney failure (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1873295\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute kidney injury (AKI) is defined as the abrupt loss of kidney function that results in a decline in glomerular filtration rate (GFR), retention of urea and other nitrogenous waste products, and dysregulation of extracellular volume and electrolytes.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The precise incidence and prevalence of pediatric AKI are not known, largely due to the lack of a consensus definition in published studies. However, in developed countries, the incidence of pediatric AKI is rising, primarily due to the increased use of intensive and advanced technology for children with chronic conditions or those who are critically ill. (See",
"      <a class=\"local\" href=\"#H17720212\">",
"       'Epidemiology'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H694161131\">",
"       'Definition'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The causes of pediatric AKI are most commonly classified by their anatomic location as follows (see",
"      <a class=\"local\" href=\"#H17605561\">",
"       'Classifications'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H17605650\">",
"       'Etiology and pathogenesis'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Prerenal AKI due to decreased renal perfusion is most commonly caused by hypovolemia, or decreased effective arterial perfusion due to heart failure, sepsis or cirrhosis (",
"      <a class=\"graphic graphic_table graphicRef50307 \" href=\"UTD.htm?4/1/4123\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H17605643\">",
"       'Prerenal AKI'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Intrinsic AKI due to injury to the renal parenchyma is most commonly caused by prolonged hypoperfusion, sepsis, nephrotoxins, or severe glomerular diseases (",
"      <a class=\"graphic graphic_table graphicRef72891 \" href=\"UTD.htm?3/57/3995\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H17605664\">",
"       'Intrinsic AKI'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Postrenal AKI results from anatomic obstructions to the lower urinary tract (See",
"      <a class=\"local\" href=\"#H17605704\">",
"       'Postrenal AKI'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most children with AKI present with signs and symptoms due to impaired renal function that include edema, reduce urine output, gross hematuria,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      hypertension. Other children are identified by elevated serum creatinine as a result of ongoing monitoring in at-risk patients or as an unanticipated laboratory finding. Other laboratory findings at presentation include hyperkalemia, serum sodium abnormalities, metabolic acidosis, hypocalcemia, and hyperphosphatemia. (See",
"      <a class=\"local\" href=\"#H17605795\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of pediatric AKI is made clinically based on the above signs and symptoms of renal impairment, and laboratory findings of renal injury including an elevated or rising serum creatinine,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      abnormal urinalysis. (See",
"      <a class=\"local\" href=\"#H1479442760\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The main differential diagnosis of AKI is an acute presentation of chronic kidney disease. The two forms of renal disease are differentiated by the duration of the disease process as well as a number of clinical findings that distinguish between the two entities (",
"      <a class=\"graphic graphic_table graphicRef82873 \" href=\"UTD.htm?28/29/29147\">",
"       table 4",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H33650600\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Further evaluation focused on identifying the underlying cause of AKI includes a complete history (",
"      <a class=\"graphic graphic_table graphicRef82870 \" href=\"UTD.htm?22/22/22891\">",
"       table 5",
"      </a>",
"      ), physical examination (",
"      <a class=\"graphic graphic_table graphicRef82871 \" href=\"UTD.htm?40/26/41387\">",
"       table 6",
"      </a>",
"      ), and laboratory evaluation. Renal imaging is often performed and rarely, a kidney biopsy is required. (See",
"      <a class=\"local\" href=\"#H17605854\">",
"       'Identifying the underlying cause'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1873518\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The editorial staff at UpToDate, Inc. would like to acknowledge Dr. Abubakr Imam, who contributed to an earlier version of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/53/19290/abstract/1\">",
"      American Society of Nephrology. American Society of Nephrology Renal Research Report. J Am Soc Nephrol 2005; 16:1886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/53/19290/abstract/2\">",
"      Devarajan P. Update on mechanisms of ischemic acute kidney injury. J Am Soc Nephrol 2006; 17:1503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/53/19290/abstract/3\">",
"      Devarajan P. Emerging urinary biomarkers in the diagnosis of acute kidney injury. Expert Opin Med Diagn 2008; 2:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/53/19290/abstract/4\">",
"      Zappitelli M. Epidemiology and diagnosis of acute kidney injury. Semin Nephrol 2008; 28:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/53/19290/abstract/5\">",
"      Andreoli SP. Acute kidney injury in children. Pediatr Nephrol 2009; 24:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/53/19290/abstract/6\">",
"      Askenazi D. Evaluation and management of critically ill children with acute kidney injury. Curr Opin Pediatr 2011; 23:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/53/19290/abstract/7\">",
"      Devarajan P. Biomarkers for the early detection of acute kidney injury. Curr Opin Pediatr 2011; 23:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/53/19290/abstract/8\">",
"      Bellomo R, Ronco C, Kellum JA, et al. Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 2004; 8:R204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/53/19290/abstract/9\">",
"      Akcan-Arikan A, Zappitelli M, Loftis LL, et al. Modified RIFLE criteria in critically ill children with acute kidney injury. Kidney Int 2007; 71:1028.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/53/19290/abstract/10\">",
"      Pl&ouml;tz FB, Bouma AB, van Wijk JA, et al. Pediatric acute kidney injury in the ICU: an independent evaluation of pRIFLE criteria. Intensive Care Med 2008; 34:1713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/53/19290/abstract/11\">",
"      Zappitelli M, Parikh CR, Akcan-Arikan A, et al. Ascertainment and epidemiology of acute kidney injury varies with definition interpretation. Clin J Am Soc Nephrol 2008; 3:948.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/53/19290/abstract/12\">",
"      Schneider J, Khemani R, Grushkin C, Bart R. Serum creatinine as stratified in the RIFLE score for acute kidney injury is associated with mortality and length of stay for children in the pediatric intensive care unit. Crit Care Med 2010; 38:933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/53/19290/abstract/13\">",
"      Moffett BS, Goldstein SL. Acute kidney injury and increasing nephrotoxic-medication exposure in noncritically-ill children. Clin J Am Soc Nephrol 2011; 6:856.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/53/19290/abstract/14\">",
"      Kavaz A, Oz&ccedil;akar ZB, Kendirli T, et al. Acute kidney injury in a paediatric intensive care unit: comparison of the pRIFLE and AKIN criteria. Acta Paediatr 2012; 101:e126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/53/19290/abstract/15\">",
"      Zappitelli M, Zhang X, Foster BJ. Estimating glomerular filtration rate in children at serial follow-up when height is unknown. Clin J Am Soc Nephrol 2010; 5:1763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/53/19290/abstract/16\">",
"      Moghal NE, Brocklebank JT, Meadow SR. A review of acute renal failure in children: incidence, etiology and outcome. Clin Nephrol 1998; 49:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/53/19290/abstract/17\">",
"      Vachvanichsanong P, Dissaneewate P, Lim A, McNeil E. Childhood acute renal failure: 22-year experience in a university hospital in southern Thailand. Pediatrics 2006; 118:e786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/53/19290/abstract/18\">",
"      Hui-Stickle S, Brewer ED, Goldstein SL. Pediatric ARF epidemiology at a tertiary care center from 1999 to 2001. Am J Kidney Dis 2005; 45:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/53/19290/abstract/19\">",
"      Van Biljon G. Causes, prognostic factors and treatment results of acute renal failure in children treated in a tertiary hospital in South Africa. J Trop Pediatr 2008; 54:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/53/19290/abstract/20\">",
"      Cataldi L, Leone R, Moretti U, et al. Potential risk factors for the development of acute renal failure in preterm newborn infants: a case-control study. Arch Dis Child Fetal Neonatal Ed 2005; 90:F514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/53/19290/abstract/21\">",
"      Aggarwal A, Kumar P, Chowdhary G, et al. Evaluation of renal functions in asphyxiated newborns. J Trop Pediatr 2005; 51:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/53/19290/abstract/22\">",
"      Mishra J, Dent C, Tarabishi R, et al. Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery. Lancet 2005; 365:1231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/53/19290/abstract/23\">",
"      Dent CL, Ma Q, Dastrala S, et al. Plasma neutrophil gelatinase-associated lipocalin predicts acute kidney injury, morbidity and mortality after pediatric cardiac surgery: a prospective uncontrolled cohort study. Crit Care 2007; 11:R127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/53/19290/abstract/24\">",
"      Bennett M, Dent CL, Ma Q, et al. Urine NGAL predicts severity of acute kidney injury after cardiac surgery: a prospective study. Clin J Am Soc Nephrol 2008; 3:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/53/19290/abstract/25\">",
"      Krawczeski CD, Woo JG, Wang Y, et al. Neutrophil gelatinase-associated lipocalin concentrations predict development of acute kidney injury in neonates and children after cardiopulmonary bypass. J Pediatr 2011; 158:1009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/53/19290/abstract/26\">",
"      Krawczeski CD, Goldstein SL, Woo JG, et al. Temporal relationship and predictive value of urinary acute kidney injury biomarkers after pediatric cardiopulmonary bypass. J Am Coll Cardiol 2011; 58:2301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/53/19290/abstract/27\">",
"      Li S, Krawczeski CD, Zappitelli M, et al. Incidence, risk factors, and outcomes of acute kidney injury after pediatric cardiac surgery: a prospective multicenter study. Crit Care Med 2011; 39:1493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/53/19290/abstract/28\">",
"      Kist-van Holthe JE, van Zwet JM, Brand R, et al. Bone marrow transplantation in children: consequences for renal function shortly after and 1 year post-BMT. Bone Marrow Transplant 1998; 22:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/53/19290/abstract/29\">",
"      Balduzzi A, Valsecchi MG, Silvestri D, et al. Transplant-related toxicity and mortality: an AIEOP prospective study in 636 pediatric patients transplanted for acute leukemia. Bone Marrow Transplant 2002; 29:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/53/19290/abstract/30\">",
"      Bailey D, Phan V, Litalien C, et al. Risk factors of acute renal failure in critically ill children: A prospective descriptive epidemiological study. Pediatr Crit Care Med 2007; 8:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/53/19290/abstract/31\">",
"      Misurac JM, Knoderer CA, Leiser JD, et al. Nonsteroidal Anti-Inflammatory Drugs Are an Important Cause of Acute&nbsp;Kidney Injury in Children. J Pediatr 2013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/53/19290/abstract/32\">",
"      Patzer L. Nephrotoxicity as a cause of acute kidney injury in children. Pediatr Nephrol 2008; 23:2159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/53/19290/abstract/33\">",
"      Elsayed EF, Reilly RF. Rhabdomyolysis: a review, with emphasis on the pediatric population. Pediatr Nephrol 2010; 25:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/53/19290/abstract/34\">",
"      Goldstein SL, Devarajan P. Pediatrics: Acute kidney injury leads to pediatric patient mortality. Nat Rev Nephrol 2010; 6:393.",
"     </a>",
"    </li>",
"    <li>",
"     The Harriet Lane Handbook, 19th ed, Tschudy KM, Arcara KM (Eds), Mosby, St. Louis 2012. p.642.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/53/19290/abstract/36\">",
"      Zappitelli M, Washburn KK, Arikan AA, et al. Urine neutrophil gelatinase-associated lipocalin is an early marker of acute kidney injury in critically ill children: a prospective cohort study. Crit Care 2007; 11:R84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/53/19290/abstract/37\">",
"      Parikh CR, Mishra J, Thiessen-Philbrook H, et al. Urinary IL-18 is an early predictive biomarker of acute kidney injury after cardiac surgery. Kidney Int 2006; 70:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/53/19290/abstract/38\">",
"      Han WK, Bailly V, Abichandani R, et al. Kidney Injury Molecule-1 (KIM-1): a novel biomarker for human renal proximal tubule injury. Kidney Int 2002; 62:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/53/19290/abstract/39\">",
"      Devarajan P, Parikh C, Barasch J. Case 31-2007: a man with abdominal pain and elevated creatinine. N Engl J Med 2008; 358:312; author reply 313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/53/19290/abstract/40\">",
"      Fahimi D, Mohajeri S, Hajizadeh N, et al. Comparison between fractional excretions of urea and sodium in children with acute kidney injury. Pediatr Nephrol 2009; 24:2409.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6126 Version 18.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-41.78.124.10-D70169F40B-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_53_19290=[""].join("\n");
var outline_f18_53_19290=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1873295\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17605554\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H694161131\">",
"      DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H694161441\">",
"      pRIFLE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17720212\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H143536415\">",
"      Co-morbid conditions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17605561\">",
"      CLASSIFICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17605650\">",
"      ETIOLOGY AND PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17605643\">",
"      Prerenal AKI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17605664\">",
"      Intrinsic AKI",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1479442591\">",
"      - Vascular disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1479442637\">",
"      - Glomerular disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17605683\">",
"      - Tubular and interstitial disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17605704\">",
"      Postrenal AKI",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17605795\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20044887\">",
"      Other laboratory findings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1479442760\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1562454639\">",
"      Laboratory tests",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1562454647\">",
"      - Serum creatinine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1562454701\">",
"      Urinalysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1562454743\">",
"      Biomarkers of AKI",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33650600\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17605854\">",
"      IDENTIFYING THE UNDERLYING CAUSE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33652950\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33653023\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33653118\">",
"      Laboratory and imaging evaluation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H33653144\">",
"      - Urinalysis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20042727\">",
"      - Tests to distinguish between prerenal and intrinsic ATN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H17605911\">",
"      Fractional excretion of sodium",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H33653840\">",
"      Other tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H20043896\">",
"      Diagnostic fluid challenge",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20044988\">",
"      Additional laboratory measurements",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1873188\">",
"      Renal imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20045402\">",
"      Renal biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1873295\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1873518\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6126\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6126|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?37/63/38900\" title=\"picture 1A\">",
"      Urinary sediment in acute tubular necrosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?31/15/31985\" title=\"picture 1B\">",
"      Tubular epithelial cell cast in acute tubular necrosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?0/1/17\" title=\"picture 1C\">",
"      Tubular epithelial cell cast in acute tubular necrosis II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?34/38/35424\" title=\"picture 2\">",
"      Photomicrograph of urine sediment with a red cell cast",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?24/0/24591\" title=\"picture 3\">",
"      Phase contrast micrograph showing dysmorphic red cells in urine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?13/47/14079\" title=\"picture 4\">",
"      Scanning electron micrograph showing dysmorphic red cells",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?14/37/14943\" title=\"picture 5A\">",
"      Photomicrograph of urine sediment with white blood cells",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?24/51/25393\" title=\"picture 5B\">",
"      White blood cell cast I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?33/49/34591\" title=\"picture 5C\">",
"      White blood cell cast II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?7/34/7715\" title=\"picture 5D\">",
"      Granular casts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?11/0/11266\" title=\"picture 5E\">",
"      Waxy cast",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6126|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/10/16555\" title=\"table 1\">",
"      Pediatric RIFLE Classification of AKI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/1/4123\" title=\"table 2\">",
"      Causes of prerenal pediatric acute kidney injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/57/3995\" title=\"table 3\">",
"      Causes of intrinsic pediatric acute kidney injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?28/29/29147\" title=\"table 4\">",
"      Features of AKI versus CKD in children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?22/22/22891\" title=\"table 5\">",
"      Potential historical findings in children with AKI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?40/26/41387\" title=\"table 6\">",
"      Physical findings in pediatric acute kidney injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/0/11275\" title=\"table 7\">",
"      Urinary indices for prerenal AKI versus ATN",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?23/40/24193?source=related_link\" title=\"calculator 1\">",
"      Calculator: Glomerular filtration rate estimate by Schwartz formula",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?25/13/25809?source=related_link\" title=\"calculator 2\">",
"      Calculator: Fractional excretion of sodium",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?24/28/25025?source=related_link\" title=\"calculator 3\">",
"      Calculator: Fractional excretion of sodium (SI units)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/30/27114?source=related_link\">",
"      Acute kidney injury (acute renal failure) in the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/11/6330?source=related_link\">",
"      Approach to the child with metabolic acidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/5/33882?source=related_link\">",
"      Causes and evaluation of hyperkalemia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/30/3562?source=related_link\">",
"      Causes of hyponatremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/42/40616?source=related_link\">",
"      Classification and incidence of childhood vasculitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/6/22632?source=related_link\">",
"      Clinical features and diagnosis of heme pigment-induced acute kidney injury (acute renal failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/49/40729?source=related_link\">",
"      Clinical manifestations and diagnosis of Henoch-Sch&ouml;nlein purpura (IgA vasculitis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/55/35704?source=related_link\">",
"      Clinical manifestations and diagnosis of Shiga toxin associated (typical) hemolytic uremic syndrome in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/36/27209?source=related_link\">",
"      Clinical manifestations and diagnosis of acute interstitial nephritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/2/44069?source=related_link\">",
"      Clinical manifestations of hyperkalemia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/0/11271?source=related_link\">",
"      Clinical presentation and diagnosis of posterior urethral valves",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/9/11418?source=related_link\">",
"      Clinical presentation and evaluation of chronic kidney disease in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/49/42773?source=related_link\">",
"      Definition of acute kidney injury (acute renal failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/60/35785?source=related_link\">",
"      Diagnostic approach to the patient with acute kidney injury (acute renal failure) or chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/7/42105?source=related_link\">",
"      Epidemiology, risk factors, and etiology of hypertension in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/54/12138?source=related_link\">",
"      Etiology and diagnosis of prerenal disease and acute tubular necrosis in acute kidney injury (acute renal failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/63/36857?source=related_link\">",
"      Etiology and evaluation of hypernatremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/62/11238?source=related_link\">",
"      Evaluation of a child with glomerular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/17/8472?source=related_link\">",
"      Fractional excretion of sodium, urea, and other molecules in acute kidney injury (acute renal failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/48/11018?source=related_link\">",
"      General principles of disorders of water balance (hyponatremia and hypernatremia) and sodium balance (hypovolemia and edema)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/11/21690?source=related_link\">",
"      Indications for and complications of renal biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/1/34839?source=related_link\">",
"      Investigational biomarkers and the evaluation of acute tubular necrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/47/20215?source=related_link\">",
"      Manifestations of and risk factors for aminoglycoside nephrotoxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/25/10647?source=related_link\">",
"      Overview and clinical assessment of the complement system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/60/22472?source=related_link\">",
"      Overview of congenital anomalies of the kidney and urinary tract (CAKUT)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/1/12311?source=related_link\">",
"      Overview of the pathogenesis and causes of glomerulonephritis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/28/25033?source=related_link\">",
"      Pathogenesis and clinical manifestations of venous thrombosis and thromboembolism in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/41/18072?source=related_link\">",
"      Pathogenesis and prevention of aminoglycoside nephrotoxicity and ototoxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/39/1657?source=related_link\">",
"      Pathophysiology and etiology of edema in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?5/46/5859?source=related_link\">",
"      Patient information: Acute kidney failure (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/30/35304?source=related_link\">",
"      Poststreptococcal glomerulonephritis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/16/42249?source=related_link\">",
"      Prevention and management of acute kidney injury (acute renal failure) in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/37/39509?source=related_link\">",
"      Radiologic assessment of renal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/54/5993?source=related_link\">",
"      Renal manifestations of Henoch-Sch&ouml;nlein purpura",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/35/10810?source=related_link\">",
"      Systemic lupus erythematosus in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/1/19481?source=related_link\">",
"      Tumor lysis syndrome: Definition, pathogenesis, clinical manifestations, etiology and risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/57/27541?source=related_link\">",
"      Uric acid renal diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/34/22058?source=related_link\">",
"      Urinalysis in the diagnosis of kidney disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_53_19291="Cancers in acromegaly";
var content_f18_53_19291=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F52927&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F52927&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Increased cancer risk in acromegaly",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Cancers",
"       </td>",
"       <td class=\"subtitle1\">",
"        Expected",
"       </td>",
"       <td class=\"subtitle1\">",
"        O/E",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        All",
"       </td>",
"       <td>",
"        116",
"       </td>",
"       <td>",
"        72",
"       </td>",
"       <td>",
"        1.6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Colon",
"       </td>",
"       <td>",
"        13",
"       </td>",
"       <td>",
"        4.2",
"       </td>",
"       <td>",
"        3.1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Esophagus",
"       </td>",
"       <td>",
"        7",
"       </td>",
"       <td>",
"        2.3",
"       </td>",
"       <td>",
"        3.1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stomach",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        1.6",
"       </td>",
"       <td>",
"        2.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Melanoma",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        0.9",
"       </td>",
"       <td>",
"        3.3",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     Common cancers occurring in 1041 men with acromegaly with no evidence for cancer at diagnosis. Excluded from this analysis were men who had gastrointestinal cancer at the time of diagnosis. There was an overall ratio of observed to expected (O/E) cancers of 1.6.",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Ron, E, Gridley, G, Hrubec, Z, et al. Cancer 1991; 68:1673.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_53_19291=[""].join("\n");
var outline_f18_53_19291=null;
var title_f18_53_19292="Neuropsych tests in cirrhosis";
var content_f18_53_19292=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F77556&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F77556&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Frequency of abnormal neuropsychological test results in patients with cirrhosis without overt signs of hepatic encephalopathy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Author (Reference)",
"      </td>",
"      <td class=\"subtitle1\">",
"       Country",
"      </td>",
"      <td class=\"subtitle1\">",
"       N",
"      </td>",
"      <td class=\"subtitle1\">",
"       NCT, percent",
"      </td>",
"      <td class=\"subtitle1\">",
"       Symbol digit, percent",
"      </td>",
"      <td class=\"subtitle1\">",
"       Other, percent",
"      </td>",
"      <td class=\"subtitle1\">",
"       Spectral EEG, percent",
"      </td>",
"      <td class=\"subtitle1\">",
"       Evoked responses, percent",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Weissenborn 1998",
"      </td>",
"      <td>",
"       Germany",
"      </td>",
"      <td>",
"       130",
"      </td>",
"      <td>",
"       17",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Quero 1996",
"      </td>",
"      <td>",
"       NL",
"      </td>",
"      <td>",
"       137",
"      </td>",
"      <td>",
"       7",
"      </td>",
"      <td>",
"       5",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       17",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Groeneweg 1998",
"      </td>",
"      <td>",
"       NL",
"      </td>",
"      <td>",
"       179",
"      </td>",
"      <td>",
"       9",
"      </td>",
"      <td>",
"       3",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       19",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Yang 1998",
"      </td>",
"      <td>",
"       Taiwan",
"      </td>",
"      <td>",
"       61",
"      </td>",
"      <td>",
"       31",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       SER: 47.5",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Amodio 1998",
"      </td>",
"      <td>",
"       Italy",
"      </td>",
"      <td>",
"       100",
"      </td>",
"      <td>",
"       19",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       Posner-test: 17",
"      </td>",
"      <td>",
"       40",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Amodio 1999",
"      </td>",
"      <td>",
"       Italy",
"      </td>",
"      <td>",
"       94",
"      </td>",
"      <td>",
"       21",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       Choice 2: 20 Scan: 23",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Only studies using age adjusted normal values listed.",
"    <div class=\"footnotes\">",
"     SER: somatosensory evoked responses.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_53_19292=[""].join("\n");
var outline_f18_53_19292=null;
var title_f18_53_19293="Unobstructed blood flow predicts TMLR outcome";
var content_f18_53_19293=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F56163&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F56163&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Unobstructed blood flow predicts TMLR outcome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 376px; height: 278px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Kaplan-Meier curves show that survival after transmyocardial laser revascularization (TMLR) is strongly affected by the overall anatomic myocardial perfusion index score (AMP); patients with a score of 1, which indicates unobstructed blood flow to a major vessel in at least one vascular territory, had a lower mortality than those who did not have adequate blood flow to any region (AMP score = 0).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Burkhoff D, Wesley MN, Rear JR, Lansing AM. J Am Coll Cardiol 1999; 34:55.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_53_19293=[""].join("\n");
var outline_f18_53_19293=null;
var title_f18_53_19294="Contents: Liver transplantation";
var content_f18_53_19294=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?3/12/3278\">",
"       Gastroenterology and Hepatology",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Liver transplantation",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Liver transplantation",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Alternatives to orthotopic liver transplantation",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/12/31944\">",
"           Hepatocyte transplantation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/4/25672\">",
"           Living donor liver transplantation",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Complications of liver transplantation",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/46/23273\">",
"           Dermatologic problems in patients who have undergone liver transplantation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/28/37319\">",
"           Diagnosis of acute cellular rejection in liver transplantation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/9/21656\">",
"           Donor selection for liver transplantation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/26/40362\">",
"           Long-term management of adult liver transplant recipients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/55/29561\">",
"           Osteoporosis after solid organ or stem cell transplantation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/12/30922\">",
"           Overview of immunosuppression in adult liver transplantation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/58/2985\">",
"           Overview of medical care of the liver transplant recipient",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/61/25559\">",
"           Patient selection for liver transplantation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/27/28090\">",
"           Pharmacology and side effects of cyclosporine and tacrolimus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/51/826\">",
"           The role of endoscopy in biliary complications after liver transplantation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/47/41718\">",
"           Treatment of acute cellular rejection in liver transplantation",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Ethics",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/13/22743\">",
"           Ethical issues in liver transplantation",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Infection",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/62/31718\">",
"           Evaluation for infection before solid organ transplantation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/48/23306\">",
"           Immunizations in solid organ transplant candidates and recipients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/47/29433\">",
"           Infection in the solid organ transplant recipient",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/28/16842\">",
"           Infectious complications in liver transplantation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/29/10714\">",
"           Prophylaxis of infections in solid organ transplantation",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Liver transplantation for nonviral causes",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/17/2330\">",
"           Acute liver failure in adults: Etiology, clinical manifestations, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/2/5160\">",
"           Liver transplantation in alcoholic liver disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/50/27430\">",
"           Liver transplantation in primary biliary cirrhosis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Liver transplantation for viral hepatitis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/17/2330\">",
"           Acute liver failure in adults: Etiology, clinical manifestations, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/29/3543\">",
"           Hepatitis D virus reinfection following liver transplantation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/2/15402\">",
"           Liver transplantation for chronic hepatitis B virus infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/5/16474\">",
"           Liver transplantation for hepatitis C virus infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/61/15321\">",
"           Solid organ transplantation in HIV-infected individuals",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Multivisceral transplantation",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/29/1497\">",
"           Overview of intestinal and multivisceral transplantation",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-2691EFC9CC-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f18_53_19294=[""].join("\n");
var outline_f18_53_19294=null;
var title_f18_53_19295="Timing anatomic risk";
var content_f18_53_19295=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F70341&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F70341&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 506px\">",
"   <div class=\"ttl\">",
"    Timing anatomic risk",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 486px; height: 259px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Sidhartha Tan, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_53_19295=[""].join("\n");
var outline_f18_53_19295=null;
